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Summary 
 
Glioblastoma (GBM) is a highly aggressive tumor that leads to the patient’s deaths within 
approximately one year. Despite recent considerable advances in our understanding of the 
pathogenetic alterations present in the tumor cells and the nature of the glioblastoma 
microenvironment, it has not been yet possible to develop effective therapies. The role of tumor-
derived metabolites in the interaction of the tumor cells with cells of the tumor stroma, e.g. 
immune cells, are a promising aspect of glioblastoma biology for defining new therapeutic 
targets.  
This thesis explores different approaches to characterize the branched-chain amino acid 
(BCAA) metabolism in the tumor-stroma interaction. In the first part I investigated whether and 
how branched-chain ketoacids (BCKAs), generated in the first step of the BCAA catabolism, are 
excreted from glioblastoma cells. I found that while the monocarboxylate transporters MCT1 and 
MCT4 are both capable and sufficient to transport BCKAs across the membranes of living cells, 
excretion of BCKAs from glioblastoma cells appears to be mediated mostly by MCT1. 
Additionally, I could show that MCT1 locates in close proximity to the BCKA-generating 
branched-chain transaminase 1 (BCAT1), suggesting possible functional interaction of the 
proteins. In the second part I investigated the fate and function of tumor-secreted BCKAs in the 
tumor-stroma interaction using macrophages as a model of the stroma compartment. Using in 
vitro isotope tracing analysis, it was demonstrated that BCKAs are taken up by macrophages 
and catabolized to BCAAs. Additionally, exposure to BCKAs reduced the phagocytic activity of 
macrophages suggesting that in glioblastoma, tumor cell-secreted BCKAs might be able to 
modulate the tumor-associated macrophages/microglia, contributing to their role in tumor 
immune suppression and supporting glioblastoma tumor growth and progression. Furthermore, I 
was able to provide evidence, that the manipulation of BCAT1 expression in the tumor 
compartment can impact the immune phenotype of tumor-associated macrophages of the 
stroma compartment via BCKAs and likely other diffusible factors.  
Ultimately, this study provides further evidence for the eminent role of BCAA catabolism 
in glioblastoma by demonstrating that tumor-excreted BCKAs might have a direct role in tumor 
immune suppression.  
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Zusammenfassung  
 
Das Glioblastom ist ein höchst aggressiver Tumor, der innerhalb von einem Jahr zum 
Tod des Patienten führt. Trotz neuester beachtlicher Fortschritte in unserem Verständnis der 
pathogenetischen Veränderungen in Tumorzellen sowie der Mikroumgebung der Glioblastome, 
gibt es bislang keine wirksamen Therapien. Ein vielversprechender Ansatzpunkt für neue 
therapeutische Zielmoleküle liegt in Metaboliten, die vom Tumor abstammen und eine Rolle in 
der Wechselwirkung zwischen Tumorzellen und Zellen im Tumor umgebenden Gewebe, wie 
z.B. Immunzellen, spielen.  
 Die vorliegende Dissertation ermittelt verschiedene Ansätze, um den Metabolismus von 
verzweigtkettigen Aminosäuren (branched chain amino acids, BCAAs) im Hinblick auf deren 
Interaktion zwischen Tumor und Stroma zu charakterisieren. Im ersten Teil untersuchte ich, ob 
und in welchem Ausmaß verzweigtkettige Aminosäuren, die im ersten Schritt des BCAA-
Katabolismus entstehen, von Glioblastomzellen ausgeschieden werden. Ich habe 
herausgefunden, dass die Ausschüttung von verzweigtkettigen Ketonsäuren (BCKAs) aus 
Glioblastomzellen hauptsächlich durch den Monocarbontransporter MCT1 erfolgt, obwohl 
sowohl MCT1 als auch MCT4 allein jeweils ausreichend sind, um BCKAs über die Membranen 
lebender Zellen zu transportieren. Darüber hinaus konnte ich zeigen, dass MCT1 in räumlicher 
Nähe zum Enzym branched-chain transaminase 1 (BCAT1) liegt, das für die Entstehung von 
BCKAs zuständig ist, und somit einen Funktionszusammenhang der Proteine vermuten lässt. 
Im zweiten Teil der Arbeit habe ich Makrophagen als Modell für das Stromakompartiment 
verwendet, um Schicksal und Funktion der vom Tumor abgesonderten BCKAs hinsichtlich 
Tumor-Stroma-Wechselwirkung zu untersuchen. Mittels in vitro Isotopentracings konnte gezeigt 
werden, dass BCKAs durch Makrophagen aufgenommen und zu BCAAs abgebaut werden. 
Außerdem wird die Phagozytoseaktivität von Makrophagen durch die Exposition zu BCKAs 
reduziert, was darauf hindeutet, dass die von Tumorzellen sekretierten BCKAs in Glioblastomen 
möglicherweise in der Lage sind, tumor-assoziierte Makrophagen/Mikrogliazellen zu regulieren, 
indem sie zu ihrer immunsuppressiven Rolle beitragen und das Fortschreiten des 
Tumorwachstums unterstützen. Zusätzlich konnte ich nachweisen, dass die Manipulation von 
BCAT1 Expression im Tumorkompartiment den Immunphenotyp der Tumor assoziierten 
 ix 
 
Makrophagen im Stroma mittels BCKAs und möglicher anderer diffusionsfähiger Faktoren 
beeinflussen kann.  
 Zusammenfassend liefert diese Dissertation den Nachweis für die bedeutende Rolle des 
BCAA Katabolismus in Glioblastomen, indem gezeigt wurde, dass vom Tumor sezernierte 
BCKAs eine direkte Rolle in der Immunsuppression spielen. 
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1. Introduction 
 
1.1. Glioma 
 
Glioma is the most common type of primary brain tumors, accounting for around 70% of 
primary central nervous system (CNS) neoplasms with an incidence of 5 – 10 people per 
100000 annually (DeAngelis, 2001; Louis et al., 2007). Gliomas originate from precursors of 
glial cells (DeAngelis, 2001) and the vast majority is characterized by diffuse infiltrative growth 
into the surrounding CNS parenchyma . Diffuse gliomas are traditionally typed as astrocytomas, 
oligodendrogliomas or as mixed gliomas/oligoastrocytomas based on histopathological features. 
However, the latter diagnosis is disappearing due to the recent progress made on molecular 
testing that provides an unambiguous diagnosis of either astrocytic or oligodendroglial tumor 
(Lenting et al., 2017; Louis et al., 2016). Furthermore, a malignancy grade is assigned to diffuse 
gliomas (World Health Organization (WHO) grade II-IV) (Lenting et al., 2017). Considering the 
gliomas with a circumscribed rather than diffuse infiltrative growth pattern, the most frequent 
examples are pilocytic astrocytoma (WHO grade I) and different variants of ependymoma (WHO 
grade I-III) (Lenting et al., 2017). The WHO grade is one indicator of the patient prognosis. 
Patients with grade I glioma survive, on average, for more than 10 years whereas for patients 
with grade II glioma this value decreases to 5 years. The survival of patients with grade III 
tumors is around 2-3 years and patients with grade IV glioma, also known as glioblastoma, 
present the poorest prognosis, frequently succumbing to the disease within 1 year (Louis et al., 
2007).   
Recently, multiple studies contributed to the identification of molecular events on the 
basis of gliomagenesis and on their clinical relevance as diagnostic, prognostic and predictive 
markers. The recently published new WHO classification utilizes some of these markers for the 
definition of particular glioma entities (Louis et al., 2016). One example are the metabolic 
enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2). Mutations in IDH genes have been 
implicated in the pathogenesis of malignant gliomas (Yan et al., 2009). Gliomas with IDH 
mutations are clinically and genetically distinct from gliomas carrying wild-type IDH genes (Yan 
et al., 2009). Point mutations in cytoplasmic IDH1 and, less frequently, mitochondrial IDH2 
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occur in 70-80% of WHO grade II or III diffuse gliomas (astrocytomas and oligodendroglial 
tumors) (Yan et al., 2009) and are rare (7-12%) in glioblastoma (Balss et al., 2008; Li et al., 
2015; Ohgaki and Kleihues, 2013; Parsons et al., 2008). These mutations cause a gain of a 
novel enzymatic activity. Instead of isocitrate being converted to α-ketoglutarate (α-KG) with 
NADPH production, α-KG is converted to 2-hydroxyglutarate (2-HG) with NADPH consumption. 
In normal cells and tissues, the concentration of 2-HG is low. However, in patients with somatic 
IDH1 or IDH2 mutations, 2-HG levels are high in glioma tissues and support tumor progression 
(Cairns et al., 2011). Furthermore, these mutations have important consequences for the 
epigenome and cause extensive DNA methylation in IDH-mutant diffuse gliomas (‘glioma-CpG 
island methylator phenotype’/G-CIMP) (Ceccarelli et al., 2016; Noushmehr et al., 2010).  
 
1.2. Glioblastoma  
 
Glioblastoma (GBM) is the highest grade (WHO grade IV) and most aggressive glioma. 
Despite aggressive treatment including surgery, adjuvant Temozolomide-based chemotherapy 
and radiotherapy, the median survival of patients after diagnosis is only around 15 months 
(Ohka et al., 2012).  
According to the 2016 CNS WHO classification, glioblastomas are divided into (1) 
glioblastoma IDH-wildtype (about 90% of cases); (2) glioblastoma IDH-mutant (about 10% of 
cases) and (3) glioblastoma NOS, referring to tumors for which full IDH evaluation cannot be 
performed (Louis et al., 2016).  
  
1.2.1. Subtype classification of GBM 
 
A gene expression-based molecular classification of glioblastoma into proneural, neural, 
classical and mesenchymal subtypes was proposed by Verhaak et al., 2010 (Verhaak et al., 
2010). Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the 
classical, mesenchymal, and proneural subtypes, respectively, whereas no distinctive mutations 
have yet been found in neural GBMs (Verhaak et al., 2010). Additionally, it was shown that the 
subtypes have specific differentiation characteristics suggesting alternative cells of origin. The 
comprehensive genomic- and genetic based classification of GBM is of major importance for 
investigation of targeted therapies and could ultimately result in personalized therapies for 
determined groups of patients with GBM (Verhaak et al., 2010).   
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More recently, DNA methylation profiling studies have identified related but different 
subgroups of GBM (Noushmehr et al., 2010; Sturm et al., 2012). Specifically, a distinct glioma-
CpG Island Methylator Phenotype (G-CIMP)-positive cluster consisting of IDH-mutated tumors 
was identified, while the remaining, non-mutated tumors were G-CIMP negative. Furthermore, a 
separate cluster of tumors containing alterations in PDGFRA, called “receptor tyrosine kinase I 
(RTK-I),” emerged corresponding to the proneural IDH wild-type subgroup proposed by Verhaak 
et al, 2010. The remaining clusters, designated “receptor tyrosine kinase II (RTK-II),” which is 
enriched for tumors carrying EGFR alterations and “mesenchymal,” containing many PTEN and 
NF1 altered tumors, were similar to the classical and mesenchymal subgroups proposed by 
Verhaak et al, 2010. 
 
1.2.2. Current treatment options 
 
The standard treatment protocol for GBM has not changed since the Food and Drug 
Administration (FDA) approval of temozolomide (TMZ) in 2005. The current treatment strategy 
for GBM comprises surgical debulking of the tumor, radiation therapy and chemotherapy. 
However, the current state of care only slightly prolongs survival, meaning that novel 
therapeutics are urgently required for the treatment of GBM.  
Several reasons contribute to the lack of approved drug-based treatment strategies. On 
the one hand, it is the high diversity in genetic aberrations in glioma combined with substantial 
intratumoral heterogeneity and the relatively low incidence of diffuse gliomas (Lenting et al., 
2017). On the other hand, gliomas are heterogeneous tumors that contain, among other stromal 
cells, a high proportion of glioma-associated macrophages and microglia that are highly 
modulated by glioma-secreted factors, including metabolites. So, with this work we aim to 
provide additional support for the concept of developing alternative therapy for glioma treatment 
based on the metabolite exchange between tumor and stromal cells. 
 
1.3. Branched-chain amino acid (BCAA) metabolism in cancer  
 
 
In contrast to most normal tissues, rapidly proliferating types of cancer have shown to 
exhibit characteristic alterations of metabolism that encompass an increased consumption of  
glucose that is mostly metabolized into lactate even in the presence of ample oxygen (Koppenol 
et al., 2011; Warburg, 1924). This phenotype is termed aerobic glycolysis or the Warburg effect 
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(Warburg, 1956). Additionally, cancers cells have been shown to exhibit an increased 
dependence on amino acid metabolism (Dang, 2012). As a consequence, cancer cells typically 
display elevated uptake of amino acids, in particular glutamine and the essential branched-chain 
amino acids (BCAAs) valine, leucine and isoleucine (Jain et al., 2012; Mayers et al., 2016). 
BCAAs participate directly and indirectly in a variety of crucial biochemical functions in the brain 
and other tissues. These include protein synthesis, the production of energy, the 
compartmentalization of glutamate, the transfer of nitrogen between tissues and synthesis of the 
amine neurotransmitters serotonin and the catecholamines dopamine and norepinephrine 
(Daikhin and Yudkoff, 2000; Suryawan et al., 1998). In cancer, it has been recently shown that 
the tissue dictates BCAA metabolism, i.e. non-small cell lung cancer (NSCLC) tumors displayed 
increased uptake of BCAA compared with normal lung, whereas pancreatic ductal 
adenocarcinoma (PDAC) tumors incorporated less BCAAs relative to normal pancreas (Mayers 
et al., 2016). 
 A refocused perspective of cancer metabolism that identifies metabolic diversity within a 
tumor offers novel therapeutic targets. Specifically, cancer cells may be starved from their fuel 
source and thereby become more sensitive to traditional therapeutic options (Nakajima and Van 
Houten, 2013). 
 
 
1.4. BCAT1 reaction 
 
The first step of BCAA catabolism involves the transfer of the primary amino group to α-
ketoglutarate, yielding glutamate and the respective branched-chain ketoacids (BCKAs). These 
reversible transamination reactions are catalyzed by the branched chain aminotransferases 
BCAT1 and BCAT2 in the cytoplasm and the mitochondria, respectively. Whereas BCAT2 
expression is nearly ubiquitous, BCAT1 expression is restricted to a small number of tissues, 
including the brain (Garcia-Espinosa et al., 2007; Sweatt et al., 2004), where BCAAs constitute 
a major source of nitrogen for the synthesis of the neurotransmitter glutamate (Garcia-Espinosa 
et al., 2007; Hutson et al., 2005). After transamination, the resulting branched-chain ketoacids 
(α-ketoisocaproate (KIC) from leucine, α-ketoisovalerate (KIV) from valine and α-keto-β-
methylvalerate (KMV) from isoleucine) undergo oxidative decarboxylation in the reaction 
catalyzed by branched-chain α-ketoacid dehydrogenase (BCKD) to acetyl coenzyme A (acetyl-
coA) and succinyl-coA, which are subsequently oxidized in the tricarboxylic acid (TCA) cycle to 
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provide macromolecule precursors and energy for ATP synthesis (Figure 1) (Kainulainen et al., 
2013; Tönjes et al., 2013). 
 
 
 
Figure 1 – Schematic representation of BCAA catabolism.  
BCAAs are catabolized, especially during exercise, to acetyl-CoA and/or succinyl-CoA, which supply the TCA cycle. 
The cytosolic BCAT1 or mitochondrial BCAT2 isoenzymes catalyze the first step of the BCAA catabolism that 
consists in the transfer of an α-amino group to α-ketoglutarate, yielding glutamate and the respective branched-chain 
α-ketoacids. Some steps of the TCA cycle were omitted for simplification. Leu: leucine; Ile: isoleucine; Val: valine; α-
KIC: α-ketoisocaproate; α-KMV: α-keto-β-methylvalerate; α-KIV: α-ketoisovalerate; α-KG: alpha-ketoglutarate; Glu: 
glutamate; OAA: oxaloacetate; TCA: tricarboxylic acid. Adapted from Kainulainen et al., 2013  (Kainulainen et al., 
2013).  
 
 
 
 
1.4.1. BCAT1 expression in cancer 
 
BCAT1 has been associated with numerous types of tumors (Chang et al., 2016b; 
Mayers et al., 2016; Xu et al., 2016). BCAT1 expression is upregulated in patients with 
hepatocellular carcinoma (Xu et al., 2016). It has been recently shown that BCAT1 is 
overexpressed in NSCLC tumors compared to normal lung tissue (Mayers et al., 2016). BCAT1 
overexpression is associated with advanced tumor status and implies adverse clinical outcomes 
of urothelial carcinoma (Chang et al., 2016b). Others have shown that BCAT1 is strongly 
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overexpressed in serous epithelial ovarian tumors and associates with cancer progression 
(Wang et al., 2015). However, BCAT1 role in tumorigenesis was firstly described in glioblastoma 
(Tönjes et al., 2013). BCAT1 is overexpressed in glioblastoma and required to support the 
sustained growth of these aggressive tumors with BCAT1 being exclusively expressed in tumors 
expressing wildtype IDH (Tönjes et al., 2013). In contrast, BCAT2 was not differentially 
expressed in IDHwt glioblastomas compared to normal brain. One implication of the group-
specific high BCAT1 expression is its possible use to identify this tumor group in a diagnostic 
setting (Tönjes et al., 2013). Furthermore, suppression of BCAA catabolism by knockdown of 
BCAT1 reduces cell proliferation in vitro and in vivo (Tönjes et al., 2013).  The authors proposed 
that the blockage of BCAA and fatty acid catabolism might lead to reduced flow of acetyl-CoA 
and succinyl-CoA into the TCA cycle thereby impacting on the synthesis of macromolecules 
required for cell division (Tönjes et al., 2013).  However, one cannot exclude the effects of the 
tumor derived metabolites in the surrounding cells, especially those from the immune 
compartment, in modulating tumor growth. 
Interestingly, a large proportion of the glutamate produced by BCAT1 was excreted from 
the glioblastoma cells (Tönjes et al., 2013). Further, it is known that BCKAs, the other product of 
the BCAT1 reaction, also can be excreted from cells, i.e. during overnight fasting when BCAAs 
are transaminated to BCKAs in muscle cells, excreted and transported to the liver for further 
oxidation (Hutson et al., 2005). 
 
1.5. Monocarboxylate transporters (MCTs) 
 
As previously referred, many cancer cells have been shown to exhibit alterations of 
metabolism including a shift away from oxidative phosphorylation and towards aerobic 
glycolysis, converting most of the incoming glucose to lactate (Semenza, 2008; Warburg, 1956). 
As a result lactate is abundantly synthesized from pyruvate (Feron, 2009), which contributes to 
the intracellular acidification inducing cellular acidosis and triggering apoptosis. Thus, in order to 
avoid apoptosis, cancer cells must sustain lactate homeostasis (Izumi et al., 2011). To be able 
to adapt to an acidic environment, cancer cells increase proton efflux through pH regulators 
such as bicarbonate transporters, proton pumps, sodium-proton exchangers and H+-linked 
monocarboxylate transporters, which are described to be upregulated in tumor cells (Izumi et 
al., 2003). Furthermore, inhibition of these adaptive mechanisms can decrease the cancer cell 
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viability and increase sensitivity to chemotherapeutic agents (Fais et al., 2007; Fang et al., 
2006). 
Transport of monocarboxylates through plasma membranes of various cells is mediated 
by a family of monocarboxylate transporters (MCTs) which can be found in a broad spectrum of 
organisms (Garcia et al., 1994; Price et al., 1998). The MCTs constitute a family of 14 
transmembrane proteins encoded by the SLC16A family of genes of which MCT1 – 4 are known 
to transport monocarboxylates together with H+ in a 1:1 stoichiometry (Halestrap, 2013; 
Halestrap and Meredith, 2004).  
Although no three-dimensional crystal structure of any member of the MCT family has 
been reported, theoretical predictions and biochemical assays using MCT1 as a model indicate 
that all the members of the MCT family share a similar overall structure that consists of 12 
transmembrane (TM) helices with intracellular C- and N-termini, two highly conserved 
sequences in TM1 and TM5 and a large cytosolic loop between TM6 and TM7 (Figure 2) 
(Halestrap, 2012).  3D models have been proposed based on extensive site-directed 
mutagenesis and molecular modeling predict that the structure of MCT1 at the plasma 
membrane alternates between two states: a closed (also designated as “inside-open”) 
conformation where the substrate-binding site is cytosolic and an open (also designated as 
“outside open”) conformation where this site is extracellular (Halestrap, 2012). 
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Figure 2 – Schematic representation of the topology of MCTs.  
MCTs contain 12 transmembrane (TM) helices (1-12) with intracellular C- and N-termini, two highly conserved 
sequences in TM1 and TM5 (represented in dark orange) and a large cytosolic loop between TM6 and TM7. The 
members from the MCT family all contain a lysine (K) in TM1 and an aspartate (D) and arginine (R) in TM 8 that are 
involved in proton and monocarboxylate binding during the translocation cycle. 
 
 
 
1.5.1. Mechanism of activity and regulatory proteins 
 
The transport of lactic acid by human MCT1 through the plasma membrane is based on 
the predicted open and closed conformation of MCTs and kinetic studies of H+-linked transport 
of lactate into erythrocytes. The uptake of lactate by MCT1 is an ordered process that starts with 
binding of a proton to K38 at the extracellular surface of MCT1, charging positively the lysine 
(Galic et al., 2003; Manoharan et al., 2006). The subsequent binding of one molecule of lactate 
forming an ionic pair promotes a change from closed to open conformation. The proton is then 
transferred to D302 residue and lactate to R306 causing the deprotonation of K38 what induces 
the return to the closed conformation. The pair H+/lac- is then released into the cytoplasm. So, 
the transport of lactic acid by MCT1 is passive and bidirectional. The intra- and extracellular 
concentrations of lactate and protons dictate whether import or export is privileged (Halestrap, 
2012; Halestrap and Meredith, 2004). 
The correct localization and activity of MCTs depends on interactions with ancillary 
proteins, primarily basigin/CD147 and embigin/gp70 (Poole and Halestrap, 1997; Wilson et al., 
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2005).  These proteins are anchored to the plasma membrane through a single transmembrane 
domain containing a conserved glutamate residue and several groups have demonstrated the 
crucial role of these proteins for the precise localization and activity of MCTs (Kirk et al., 2000; 
Ovens et al., 2010; Wilson et al., 2005). In the absence of the ancillary proteins, MCTs are not 
able to reach their final position and accumulate in the Golgi apparatus (Kirk et al., 2000; Wilson 
et al., 2005). It has been described that basigin is more widely expressed compared to embigin, 
and appears more frequently as partner for MCT1, MCT3 and MCT4, whereas MCT2 
preferentially interacts with embigin (Ovens et al., 2010; Wilson et al., 2005). 
Other proteins have been suggested to interact with MCTs. Carbonic anhydrase II (CAII) 
and CAIV, cytosolic and extracellular CA isoforms, respectively, can also establish interactions 
with MCT/basigin complexes, enhancing the activity of the transporters (Klier et al., 2014; Klier 
et al., 2011). It has been proposed that CAs supply MCTs with protons increasing MCT activity 
(Klier et al., 2014; Klier et al., 2011). Specifically, CAII, directly bound to MCT1, can act as a 
“H+-collecting/distributing antenna” increasing the concentration of protons in the vicinity of 
MCTs to support proton/lactate co-transport (Figure 3) (Becker et al., 2011; Klier et al., 2014). 
 
 
Figure 3 – Hypothetical model of the interaction between MCT1/4, CAII, CAIV. 
Extracellular CAIV is anchored to the extracellular side of the plasma membrane by glycosyl-phosphatidyl-inositol 
(GPI) anchor. CAIV is located close to MCT1 and MCT4 by direct interaction with CD147 (basigin), the chaperon of 
the two transporters. On the intracellular site CAII is located close to the transporters by binding to their C-terminal 
tail. In this position, CAIV and CAII can act as an extra- and intracellular proton-collecting antenna for the transporter, 
which shuttles protons between transport pore and surrounding protonatable residues (gray circles) to facilitate 
shuttling of H
+ 
and lactate across the cell membrane. Lac
-
: lactic acid. Figure taken from Klier et al., 2014 (Klier et al., 
2014). 
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1.5.2. Substrates 
 
It has been proposed that MCT1 – 4 isoforms show preference for short chain 
monocarboxylates, including those substituted on positions two and three, such as L-lactate, D-
lactate, pyruvate, β-hydroxybutyrate and acetoacetate. In quantitative terms, lactate has been 
identified as one of the most important metabolites for these transporters with a stereoselectivity 
for L- over D-lactate (Halestrap, 2012).  
Previous reports described that MCT4 (SLC16A3) preferentially exports lactate, while 
MCT1 (SLC16A1) can facilitate both lactate import and export depending on the pH gradient 
(Draoui and Feron, 2011). MCT4 has the lowest affinity for lactate, is encoded by a hypoxia-
inducible factor (HIF) HIF-1α-target gene (Ullah et al., 2006), and is therefore responsible for the 
export of lactic acid from glycolytic tumor cells (Dimmer et al., 2000). It has been proposed that 
MCT4 has a central role in the regulation of intracellular pH although it has only a low affinity for 
lactate, its high turnover rate ensures efficient proton export (Chiche et al., 2012).  
MCT1 has an intermediate affinity for lactate and is ubiquitously expressed in healthy 
and cancer tissues. In cancer, it was proposed to facilitate lactate uptake fueling the oxidative 
metabolism of oxygenated tumor cells in a newly described metabolic pathway involving lactate 
oxidation into pyruvate to fuel the TCA cycle (Sonveaux et al., 2008).  
MCT2 is reported to be expressed in the mitochondrial membrane, where it is involved in 
the import of pyruvate following lactate oxidation (Koukourakis et al., 2006). MCT3 exports 
lactate, but is only reported to be expressed in retinal pigment epithelium and choroid plexus 
epithelium (Philp et al., 2001). 
Besides their role as lactate transporters, MCTs have affinity for the transport α-
ketoacids (Manning Fox et al., 2000). Affinity studies performed on Xenopus oocytes indicate 
Km values of MCT4 and MCT1 for α-ketoisocaproate of 95mM and 0.7mM, respectively and for 
α-ketoisovalerate of 113mM and 1.3mM, respectively (Table 1) (Manning Fox et al., 2000).  
Furthermore, it was shown that the transport of α-ketoisocaproate (KIC) in neurons 
involves one of the MCT proteins (Mac et al., 2000).  
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Table 1 – Km values of different MCT isoforms for a range of monocarboxylates.  
Values are given ± Standard Error (SE). Adapted from Manning Fox et al., 2000 (Manning Fox et al., 2000). 
Substrate MCT4 Km 
(Oocytes) 
(mM) 
MCT1 Km 
(Tumor cells) 
(mM) 
MCT1 Km 
(Oocytes) 
(mM) 
MCT2 Km 
(Oocytes) 
(mM) 
Formate >500 >100 - - 
Bicarbonate >500 - - - 
Oxamate >500 49 - - 
Glyoxylate >500 63 - - 
L-Lactate 28±4 4.5 3.5 0.74 
D-Lactate 519±33 27.5 >60 - 
Pyruvate 153±6 0.7 1.0 0.08 
S-Chloropropionate 46±2.5 0.7 - - 
R- Chloropropionate 51±2.6 0.7 - - 
D-L-α-Hydroxybutyrate 56±3 2.6 - - 
L-β- Hydroxybutyrate 824±64 11.4 - 1.2 
D-β- Hydroxybutyrate 130±9.6 10.1 - 1.2 
γ- Hydroxybutyrate >500 7.7 - - 
Acetoacetate 216±27 5.5 - 0.8 
α-Ketobutyrate 57±3.3 0.2 - - 
α-Ketoisocaproate 95±5.1 - 0.7 0.1 
α-Ketoisovalerate 113±9.6 - 1.3 0.3 
β-Phenylpyruvate >500 - - - 
 
Km values were derived by least-squares regression to the Michaelis-Menten equation. 
 
 
 
 
 
1.5.3. Inhibitors 
 
Several MCT inhibitors have been identified over the past decades. Phloretin, flavonoids 
such as quercetin, stilbene disulphonates (including DIDS and 4,4′-dibenzamidostilbene-2,2′-
disulphonate [DBDS]), and α-cyano-4-hydroxycinnamate (CHC) and its analogs were the first 
inhibitors to be described but all have off-target effects (Halestrap, 2012; Halestrap and Price, 
1999). More recently other inhibitors have been developed that exhibit high affinity for MCTs 
(Bola et al., 2014; Ovens et al., 2010). The compound AZD3965 is a dual MCT1 and MCT2 
inhibitor that is currently being evaluated as an anticancer agent in Phase I clinical trials for 
patients with prostate cancer, gastric cancer or diffuse large B cell lymphoma (Polanski et al., 
2014).  The related compound AR-C155858 is a dual MCT1/2 inhibitor that inhibits preferentially 
MCT1 (Ki ~ 2nM) but also MCT2 when it is bound to ancillary protein basigin but not when it is 
bound to its preferred chaperone embigin (Nancolas et al., 2015; Ovens et al., 2010). AR-
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C155858 does not inhibit MCT4 and the recent identification of key binding site residues in the 
intracellular substrate-binding cavity that differ significantly between MCT1/MCT2 and MCT4 
can explain the differences in inhibitor binding, contributing to the isoform selectivity of AR-
C155858 (Nancolas et al., 2015) (Figure 4). AR-C155858 binds to MCT1 from the intracellular 
side and involves TMs helices 7-10 and kinetic studies suggest that it is a non-competitive 
inhibitor (Ovens et al., 2010).  
 
 
 
Figure 4 – Schematic representation of the proposed mechanism of inhibition by AR-C155858. 
AR-C155858 crosses the plasma membrane to enter MCT1 in the inward-open conformation. An intermediate 
conformation is adopted, allowing binding of the inhibitor by interaction with residues in the intracellular half including 
Asn147 (helix 5), Arg306 (helix 8) and Ser364 (helix 10). A further conformational change allows the movement of 
AR-C155858 into the channel of MCT1, interacting with residues in the extracellular half including Lys38 (helix 1), 
Asp302 (helix 8), Phe360 (helix 10), Lys274 and Ser278 (helix 7). Figure taken from Nancolas et al,2015 (Nancolas 
et al., 2015) 
 
 
1.5.4. Cell-specific distribution 
 
Expression of MCT1 is considered ubiquitous since it is found in several tissues and 
organs, whereas the expression of the other three members is known to be more restricted 
(Perez-Escuredo et al., 2016). Focusing on brain, MCT1 is expressed primarily in endothelial 
cells, while MCT4 is expressed mainly in astrocytes. Neurons, on the other hand, express 
primarily MCT2. The difference in MCT isoforms between astrocytes and neurons is the basis of 
the lactate shuttle hypothesis, which states that lactate is produced by astrocytes and used by 
neurons (1.6.1) (Kennedy and Dewhirst, 2010; Pellerin, 2003).  
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1.5.5. MCTs expression in cancer 
 
 
In tumor cells take-up or export of lactate are dependent on oxygen availability, lactate 
concentration and expression of the MCT subtype at the plasma membrane (Semenza, 2008) 
Recent data suggest that MCT1 can transport lactate into and out of tumor cells. Whereas most 
oxidative (opposing to glycolytic) cancer cells import lactate through MCT1 to fuel mitochondrial 
respiration, the role of MCT1 in glycolysis-derived lactate efflux remains less clear (Boidot et al., 
2012). 
 In tumors, it has been described that MCT1 and MCT4 are overexpressed in the plasma 
membrane of glioblastomas, compared with non-neoplastic brain tissues (Miranda-Goncalves et 
al., 2013). Other studies have shown that MCT1 and MCT4 overexpression in human 
neuroblastoma, cervix and colorectal cancers, was associated with bad prognosis of cancer 
(Fang et al., 2006; Pinheiro et al., 2009; Pinheiro et al., 2008; Sonveaux et al., 2008). It was 
also shown that high expression of both MCT1 and MCT4 correlates with the invasiveness of 
lung cancer cells (Izumi et al., 2011). 
 A recent study reveals that MCT1 and MCT4 expression is significantly reduced in 
mutant IDH1 compared to wild-type IDH1 gliomas (Viswanath et al., 2016). This observation 
suggests that reduced MCT expression is part of the metabolic reprogramming of mutant IDH1 
gliomas (Viswanath et al., 2016). 
 Fewer reports are available that evaluate MCT2 and MCT3 expression in cancer. A 
recent study pointed to an overexpression of MCT2 in pancreatic cancer and suggested it as a 
putative biomarker and molecular target (Pertega-Gomes et al., 2015). Others have shown that 
MCT3 is expressed in both cancer and stromal cells in NSCLC (Eilertsen et al., 2014). 
 
1.6. Metabolite exchange between tissue compartments 
  
1.6.1. Astrocyte-neuron lactate shuttle 
 
MCTs mediate lactate exchange between astrocytes and neurons in the brain (Perez-
Escuredo et al., 2016). Astrocytes import glucose via glucose transporters (GLUT) and convert 
it to pyruvate and ATP via glycolysis, and pyruvate to lactate via lactate dehydrogenase A 
(LDHA). Lactate is exported together with protons via MCT4. Neurons import lactate via MCT2 
and oxidize it to pyruvate via lactate dehydrogenase B (LDHB) fueling the TCA cycle to support 
ATP production via oxidative phosphorylation (Perez-Escuredo et al., 2016). 
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1.6.2. BCAT cycle in the brain 
 
An analogous transfer of metabolites, involving the coupled exchange of the amino acids 
glutamate and glutamine and the branched chain amino acids and ketoacids (BCAT cycle) has 
been shown to occur in the normal brain and is crucial for maintaining nitrogen balance (Figure 
5) (Butt et al., 2012). Exchange of these metabolites between neurons and astrocytes has been 
demonstrated in co-culture systems (Bak et al., 2013; Leke et al., 2011). 
 
 
 
 
 
 
 
1.6.3. Lactate shuttle in tumors   
 
Recent studies suggested that different aspects of tumor metabolism, i.e. lactate 
production and consumption, are compartmentalized between tumor cells and fibroblast stroma 
cells in mammary carcinoma. In this model lactate is produced and excreted via MCT4 by 
stroma cells and taken up by tumor cells via MCT1 for ATP production (Migneco et al., 2010; 
Nakajima and Van Houten, 2013). 
Others have provided evidence for the existence of a lactate shuttle in prostate cancer, 
with cancer associated fibroblasts (CAFs) excreting lactate, via MCT4, that is imported by the 
tumor cells via MCT1. Furthermore, high MCT4 expression in CAFs with concomitant strong 
MCT1 expression in cancer cells was associated with poor clinical outcome (Pertega-Gomes et 
al., 2014). It has been recently shown that lactate produced by multiple myeloma cell lines and 
bone marrow stromal cells contributes to the survival of such tumor cells in an autocrine or 
paracrine manner (Fujiwara et al., 2015). 
Figure 5 – Cell to cell transfer of branched-chain amino acids (BCAAs) and branched-chain ketoacids (BCKAs) 
for de novo glutamate synthesis in normal brain. 
 (1) glutamine synthetase; (2) glutaminase; (3) glutamate dehydrogenase. mBCAT, mitochondrial BCAT; cBCAT, 
cytosolic BCAT; TCA, tricarboxylic cycle; α-KG, α-ketoglutarate. Adapted from Butt et al,2012 (Butt et al., 2012)   
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This exchange of metabolites between tumor and stromal cells provides a system by which 
cancer cells may adapt to or maximize the use of available resources, thereby increasing their 
capacity to grow and metastasize. Components involved in this process such as metabolite 
transporters and enzymes may serve clinically as prognostic indicators and their inhibition as 
potential therapeutic targets (Nakajima and Van Houten, 2013). 
 
1.7. Glioblastoma microenvironment  
 
The resistance of glioblastoma to standard therapies is believed to result from their 
heterogeneity and the unique tumor microenvironment composed by multiple types of cells, 
including malignant cells, extracellular matrix, nonmalignant resident stromal cells such as 
activated fibroblasts and migratory hematopoietic cells such as macrophages (Figure 6) 
(Charles et al., 2012; Hanahan and Weinberg, 2011). The interactions among the components 
of a tumor microenvironment modulate tumor progression, invasion and angiogenesis (Balkwill 
et al., 2005). The inflammatory microenvironment of tumor tissues consists of macrophages, 
dendritic cells, mast cells and T cells (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; 
Nakayama et al., 2004).  
Macrophages have traditionally been classified as tumor-suppressive (M1) or tumor-
supportive (M2) (Mantovani et al., 2002).  M1 macrophages are classically activated by 
interferon (IFN)-γ, whereas alternative activation by interleukin (IL)-4 and IL-13 drives 
macrophages toward the M2 phenotype (Mantovani et al., 2002). It is important to note that fully 
polarized M1 and M2 macrophages are the extremes of a continuum of functional states 
(Mantovani et al., 2002). 
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Figure 6 – Schematic representation of glioblastoma microenvironment.  
Glioblastoma microenvironment is composed by several stromal cell types that include but are not limited to 
astrocytes, pericytes, fibroblasts, endothelial cells and macrophages.  BTSC: brain tumor stem cell-like. Adapted from 
Charles et al, 2012 (Charles et al., 2012) 
 
 
1.7.1. Tumor-associated macrophages/microglia 
 
The interactions of macrophages and microglia with gliomas have been extensively 
studied, and whether these cells function to suppress or enhance glioma growth is still a matter 
of debate. 
Tumor–associated macrophages (TAMs) are a major component of the tumor leukocyte 
infiltrate, accumulating in hypoxic areas of tumors (Bingle et al., 2002; Pollard, 2004) due to HIF-
1-dependent upregulation of the chemokine receptor CXCR4 (Schioppa et al., 2003). TAMs 
recruitment and survival is sustained by cytokines present in the tumor microenvironment 
(Balkwill et al., 2005). It has been described that in response to cytokines such as TGF-β, IL-10 
and M-CSF, TAMs acquire M2 properties, promoting tumor proliferation (Pollard, 2004; Wyckoff 
et al., 2004).  
The origin of TAMs and mechanism of their recruitment and differentiation is not entirely 
clear. There is evidence that both tissue-resident and recruited macrophages may coexist in 
tumors (Kim and Bae, 2016). On the one hand, there is evidence that resident microglia, and 
not peripheral macrophages, is the main source of mononuclear cells in gliomas (Muller et al., 
2015). Besides brain microglia, lung alveolar and peritoneal macrophages, Kupffer cells and 
epidermal Langerhans cells, all derived from primitive yolk sac precursors, can be self-
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maintained locally (Kim and Bae, 2016). On the other hand, studies performed in mice revealed 
that mammary tumor growth induces the accumulation of TAMs that are phenotypically and 
functionally distinct from mammary tissue macrophages and differentiate from CCR2+ 
inflammatory monocytes (Franklin et al., 2014).  
In glioma, glioma-infiltrating macrophages and microglia (GAMs) constitute a substantial 
portion of the tumor mass that can be as high as one in every three cells (Sarkar et al., 2014). 
Predominantly, gliomas appear to suppress the immune surveillance functions of 
macrophages and microglia. It is reported that glioma switches the infiltrating 
macrophages/microglia toward an immunosuppressive phenotype characterized by reduced 
phagocytic activity, production of less inflammatory cytokines and secretion of matrix 
metalloproteinases (MMP) enzymes, thus promoting glioblastoma invasion (Hussain et al., 
2006; Li and Graeber, 2012). Others have shown that exposure of microglia to glioblastoma 
conditioned medium modulates microglia migration and phagocytic activity in vitro 
(D'Alessandro et al., 2013).  
In contrast, there is evidence that macrophages and microglia attempt to counteract the 
activity of glioma cells. Macrophage and microglia factors stimulate the apoptosis of glioma cells 
in culture (Hwang et al., 2009) and in vivo (Brantley et al., 2010) and the toll-like receptor 3 
agonist poly(I:C) causes microglia to secrete factors that kill glioma cells in culture (Kees et al., 
2012).  
 
1.7.2. Expression profile of glioma associated macrophages/microglia 
 
As previously referred, glioma-associated microglial cells and infiltrating macrophages 
(GAMs) make up the largest portion of tumor-infiltrating cells, contributing to up to 30% of the 
entire glioma mass (Charles et al., 2012; Sarkar et al., 2014). Lately, several studies have been 
conducted in order to refine the phenotypic and/or genotypic characterization of glioblastoma-
infiltrating innate immune cells. According to a recent study using genome-wide microarray 
expression analysis, GAMs display an expression profile different from M1 and M2 polarization 
and express the pro-tumorigenic genes GPNMB and SPP1 (Szulzewsky et al., 2015).  Another 
recent study, combining immune phenotyping, whole-genome microarray analysis and 
microRNA expression profiling revealed that glioblastoma-infiltrating innate immune cells 
resemble, contrary to the current dogma, a nonpolarized M0 macrophage phenotype 
(Gabrusiewicz et al., 2016). 
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1.7.3. Effect of tumor secreted factors on macrophage polarization   
 
Tumor cell-derived factors play an important role in tumor cell-macrophage 
communication.  
In glioma, recent findings demonstrate the importance of tumor-cell-derived versican, 
also known as CSPG2, in tumor-macrophage communication (Hu et al., 2015). Versican 
released from glioma cells promotes tumor expansion via glioma-associated 
microglia/macrophages Toll-like receptor 2 signaling (Hu et al., 2015).  
Others have shown that the production and release of cytokines by tumor cells can 
impact on macrophage survival and polarization (Ries et al., 2014; Zhou et al., 2015). Periostin 
secreted by glioblastoma stem cells recruits M2 tumor-associated macrophages and promotes 
malignant growth (Zhou et al., 2015). Specifically, the authors showed that glioma stem cells 
secrete periostin to attract circulating monocytes that are differentiated into M2 TAMs that 
promote tumor growth. Targeting periostin on glioma stem cells attenuated the differentiation of 
M2 TAMs and halted tumor progression (Zhou et al., 2015). Additionally, experiments using 
tumor conditioned media (TCM) from various cell lines derived from different tumor entities 
revealed that macrophages differentiated with TCM containing high colony-stimulating factor 1 
(CSF-1) and low granulocyte-macrophage colony-stimulating factor (GM-CSF) levels displayed 
an M2-like phenotype, whereas macrophages differentiated with TCM containing high GM-CSF 
showed a mixed M1/M2 phenotype (Ries et al., 2014). These studies show that the levels of 
cytokines present in the tumor microenvironment influence and shape the cells from the immune 
compartment impacting on their anti-tumoral or pro-tumoral state of activation.  
Among the tumor-derived signals, metabolites have also been shown to impact on the 
phenotype of the surrounding stromal cells (Colegio et al., 2014; De Simone et al., 2013; Patel 
et al., 2017). Lactic acid produced by tumor cells has a critical function as a signaling molecule, 
namely through the induction of Vascular endothelial growth factor (VEGF) and the M2-like 
polarization of TAMs (Colegio et al., 2014). Additionally, lactate-induced expression of arginase 
1 by macrophages has in turn an important role in promoting tumor growth (Colegio et al., 
2014). Branched-chain amino acids influence the immune properties of microglial cells and their 
responsiveness to pro-inflammatory signals (De Simone et al., 2013). High concentrations of 
BCAAs (10mM) polarize microglial cells towards the M2 state, with enhanced interleukin (IL) IL-
10 expression and phagocytic activity (De Simone et al., 2013).  
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1.8. Aims of the study 
 
The first aim of the present study is to investigate the involvement of MCTs in the 
transport of BCKAs across cell membranes using two distinct approaches: 1) heterologous 
expression of MCTs and BCAT1 in Xenopus oocytes and the characterization of BCKAs 
transport in this model system and 2) modulation of MCTs transport activity in glioblastoma cell 
lines.  
The second aim is to clarify the fate and function of tumor-secreted BCKAs in the tumor-
microenvironment interaction using macrophages as a model of the stroma compartment. 
Specifically, I want to address the question whether stromal cells, i.e. tumor-associated 
macrophages, take up and metabolize BCKAs and whether BCKAs affect the macrophages’ 
phenotype.  
In additional work I aim to evaluate the effect of manipulating BCAT1 expression in 
tumor cells on the stromal cell phenotype. 
Ultimately, this study aims to contribute to the identification of new therapeutic targets for 
glioblastoma by studying BCAA catabolism in the tumor-stroma interaction.  
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2. Materials and methods 
2.1. Materials 
2.1.1. Antibodies 
 
Antibody Company 
anti-β-tubulin 
anti-rabbit IgG-HRP  
anti-mouse IgG-HRP  
anti-BCAT1 
Sigma-Aldrich, Munich, Germany  
sc-2004, Santa Cruz Biotechnology, Dallas, TX, USA 
sc-2005, Santa Cruz Biotechnology, Dallas, TX, USA 
Insight Biotechnology limited (Wembley, UK) 
anti-MCT1 ab90582, Abcam, Cambridge, UK 
anti-MCT1 
anti-MCT4  
AB3538P, Millipore 
sc376140, Santa Cruz Biotechnology, Dallas, TX, USA 
anti-PGK1  
anti-MCT2 
FITC anti-human CD14  
FITC Mouse IgG1 κ Isotype Control 
Streptavidin-Phycoerythrin (SAv-PE) 
GTX107614, GeneTex, Irvine, CA,  USA 
PA5-50518, Thermo Fisher Scientific 
301804, Biolegend, San Diego, CA, USA 
555748,BD Biosciences, Heidelberg, Germany 
554061, BD Biosciences, Heidelberg, Germany 
  
2.1.2. Buffers and solutions 
 
Solution Composition 
FACS buffer 
LB (Luria Bertani) medium 
LB Agar  
 
Transfer buffer 1X 
TRIS buffered saline (TBS) 1X 
TRIS-Borat-EDTA (TBE) 1X  
TBS-T 
Stripping buffer 
5 % FCS in PBS 1X  
0.5 % (w/v) NaCl, 1 % (w/v) Tryptone, 0.5 % (w/v) Yeast extract  
0.5 % (w/v) NaCl, 1 % (w/v) Tryptone, 0.5 % (w/v) Yeast extract, 
1.6 % (w/v) Agarose  
25 mM Tris, 200 mM glycine, 20 % methanol  
150 mM NaCl, 10 mM Tris, pH 7.5  
0.445 M Tris-Borat, 10 mM EDTA  
TBS 1X, 1:1000 (v/v) Tween 20 
62.5 mM Tris pH 6.8, 2% SDS, 100mM β-mercaptoethanol 
  
2.1.3. Cell culture reagents and material 
 
Reagent/ Material Distributor 
Accutase  
Biocoll 
Carboxyfluorescein succinimidyl ester (CFSE) 
CCL2, human recombinant protein 
Cell culture flasks and multi-well plates 
CD14 MicroBeads, human 
Sigma-Aldrich, Munich, Germany 
Biochrom GmbH, Berlin, Germany 
BD Biosciences, Heidelberg, Germany 
R&D Systems, Minneapolis, MN, USA 
Tritech Research, Los Angeles, USA  
Miltenyi Biotec, Bergisch Gladbach, 
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ChamberSlides, Lab-Tek II, 8 Kammern, Glas 
 
Corning® Transwell® polycarbonate membrane 
cell culture inserts 5.0μm pore 
Cryo tubes  
Dimethyl sulphoxide (DMSO)  
 
DharmaFECT 1 transfection reagent  
DMEM (Dulbecco’s modified eagle medium) 
5796  
DMEM 5921 
DMEM 6046 
Doxycycline  
Fetal calf serum (FCS)  
Leucosep™ tubes, 50 mL 
 
L-Glutamine  
 
MACS buffer 
 
MACS human CD14 Microbeads 
 
MACS LS separation columns 
 
MACS Magnet and stand 
 
M-CSF, human recombinant 
 
Opti-MEM I reduced serum medium  
 
PBS Dulbecco’s 
Penicillin/Streptomycin (10000 U/ml, 100 μg/ml)  
 
Phorbol 12-myristate 13-acetate (PMA) 
RPMI (Roswell Park Memorial Institute) 1640 
Tet system approved Fetal Bovine Serum (FBS) 
 
Trypsin EDTA solution (0.5 %)  
α-Keto-β-methylvaleric acid (KMV) sodium salt 
 
α-Ketoisovaleric acid (KIV) sodium salt 
 
α-Ketoisovaleric acid (KIV) sodium salt 
(13C5,98%) 
  
α-Ketoisocaproic acid (KIC) sodium salt  
α-Ketoisocaproic acid (KIC) sodium salt (1,2-
13C2, 99%)  
 
Germany 
Thermo Fischer Scientific, Langenselbold, 
Germany  
Sigma-Aldrich, Munich, Germany 
 
Nunc, Wiesbaden, Germany  
Sigma-Aldrich, Munich, Germany  
 
Dharmacon Inc., Lafayette, Colorado, EUA 
Sigma-Aldrich, Munich, Germany  
 
Sigma-Aldrich, Munich, Germany  
Sigma-Aldrich, Munich, Germany  
Sigma-Aldrich, Munich, Germany  
Merck Millipore, Darmstadt, Germany  
Greiner Bio-One International GmbH, 
Kremsmunster, Austria 
Thermo Fischer Scientific, Langenselbold, 
Germany  
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Thermo Fischer Scientific, Langenselbold, 
Germany  
Life Technologies, Carlsbad, USA 
Thermo Fischer Scientific, Langenselbold, 
Germany  
Sigma-Aldrich, Munich, Germany  
Life Technologies, Carlsbad, US 
Clontech/Takara, Saint-Germain-en-Laye 
France 
Sigma-Aldrich, Munich, Germany  
sc-214140, Santa Cruz Biotechnology, 
Dallas, TX, USA 
198994-5G, Sigma-Aldrich, Munich, 
Germany  
Cambridge Isotope Laboratories, Inc., 
Andover, MA, USA 
 
Sigma-Aldrich, Munich, Germany  
Cambridge Isotope Laboratories, Inc., 
Andover, MA, USA 
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2.1.4. Cell lines and biological material 
 
 
Cell line/biological material Distributor 
LN-229 
One Shot TOP10 Chemically Competent E.coli 
U251-MG 
U87-MG 
U937 (GFP transduced) 
 
ATCC 
Life Technologies GmbH 
ATCC 
ATCC 
Provided by Dr.Martina Seiffert, DKFZ, 
Heidelberg 
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2.1.5. Chemicals and reagents  
 
Reagent Distributor 
Agarose  
Ampicillin  
AR-C155858 (MCT1/2 inhibitor) 
Bicinchoninic acid (BCA)  
Bovine serum albumin (BSA) 
Copper-(II)-sulphate  
Dithiotreitol (DTT) (0.1 M)  
DNA marker (1kb)  
dNTP mix (100 μM each)  
Ethanol  
Ethidium bromide  
Ethylendiaminetetracetate (EDTA) (25 mM)  
EDTA 1X 
FD green buffer (10X) 
Formamide  
Glycerol  
Methanol  
NaCl 0.9% 
Nuclease-free water  
NuPAGE® LDS sample buffer (4X)  
NuPAGE® SDS running buffer (20X)  
Paraformaldehyde (PFA)  
Protease and phosphatase inhibitor cocktail 
(PIC) (1X) 
Pierce ECL Western blotting substrate  
Random primer mix  
RIPA-lysis buffer  
S.O.C medium 
Sodium dodecyl sulfate (SDS)  
Sodium acetate  
Spectra high range multicolor protein ladder  
Tris-(hydroxymethyl)-aminomethan (TRIS)  
Triton X-100  
Tween 20 
Whole milk powder  
β-Mercaptoethanol 
Sigma-Aldrich, Munich, Germany  
Roche Diagnostics, Mannheim, Germany  
Tocris Bioscience, Bristol, UK  
Sigma-Aldrich, Munich, Germany  
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
Fermentas, St Leon-Rot, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
Merck Millipore, Darmstadt, Germany  
Sigma-Aldrich, Munich, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
Merck Millipore, Darmstadt, Germany  
Carl Roth, Karlsruhe, Germany  
Sigma-Aldrich, Munich, Germany  
Braun, Melsungen, Germany 
Ambion, Austin, USA  
Life Technologies, Darmstadt, Germany  
Life Technologies, Darmstadt, Germany  
Sigma-Aldrich, Munich, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
 
Thermo Fischer Scientific, Langenselbold, Germany  
New England Biolabs (NEB), Ipswich, USA  
Sigma-Aldrich, Munich, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
Sigma-Aldrich, Munich, Germany  
Carl Roth, Karlsruhe, Germany  
Fermentas, St Leon-Rot, Germany  
Carl Roth, Karlsruhe, Germany  
Sigma-Aldrich, Munich, Germany  
Sigma-Aldrich, Munich, Germany  
Carl Roth, Karlsruhe, Germany  
Sigma-Aldrich, Munich, Germany  
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2.1.6. Databases 
 
Database site 
Ensembl  
Gene Cards (Human Genes Database)  
HMDB 
NCI-60 
PubMed 
R2: Genomics Analysis and Visualization 
Platform 
Universal Probe Library Roche 
 
www.ensembl.org  
www.genecards.org/  
http://www.hmdb.ca/ 
http://129.187.44.58:7070/NCI60/ 
www.ncbi.nim.nih.gov/PubMed/  
http://hgserver1.amc.nl/cgi-bin/r2/main.cgi 
 
https://qpcr.probefinder.com/organism.jsp 
 
  
 
2.1.7. Enzymes 
 
Enzyme Supplier 
BamHI FastDigest (FD) 
DNase I  
EUROTAQ DNA polymerase 
HindIII FastDigest (FD) 
Thermo Fischer Scientific, Langenselbold, Germany  
Thermo Fischer Scientific, Langenselbold, Germany  
EuroClone/Biozol, Eching, Germany   
Thermo Fischer Scientific, Langenselbold, Germany  
PRECISOR High-Fidelity DNA 
Polymerase  
SuperScript II Reverse Transcriptase  
BioCat, Heidleberg, Germany  
 
Thermo Fischer Scientific, Langenselbold, Germany 
T4 DNA ligase Thermo Fischer Scientific, Langenselbold, Germany  
 
  
 
2.1.8. Instruments 
 
Instrument Distributor 
ABI PRISM 7900HT Fast Real Time PCR 
System  
 
Acquity FLR detector 
Acquity H-class UPLC system 
 
Agilent 7890 Gas Chromatograph  
 
Agilent 5975C Mass Spectrometer 
 
Applied Biosystems / Life Technologies, Carlsbad, 
USA 
 
Waters GmbH, Eschborn, Germany 
Waters GmbH, Eschborn, Germany 
 
Agilent Technologies Deutschland GmbH, 
Waldbronn, Germany  
Agilent Technologies Deutschland GmbH, 
Waldbronn, Germany  
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Axioplan 2 imaging microscope 
 
Carl Zeiss Microscopy, Jena, Germany 
Cell Observer microscope 
Centrifuge Heraeus Sepatech Varifuge 
3.0R  
Eppendorf MastercyclerR Thermal Cycler 
S  
FACS Canto IITM  
Fusion solo S  
Leica DM IRBE microscope 
NanoDrop ND-1000 Spectrometer  
Carl Zeiss Microscopy, Jena, Germany 
M&S Laborgerate GmbH, Wiesloch, Germany 
 
Eppendorf, Hamburg, Germany 
 
BD Biosciences, Heidelberg, Germany 
Vilber Lourmat, Eberhardzell, Germany  
Leica Microsystems, Wetzlar, Germany 
NanoDrop, Wilmington, USA 
Pipettes (2μl, 10μl)  
Pipettes (20μl, 100μl, 200μl, 1000μl)  
SDS-PAGE Gel Apparatus  
Steri-Cycle CO2 Cell Culture Incubator 
UV-Gel Documentation System  
Vi-CELL XR 2.03  
Western Blot Transfer Device  
Eppendorf, Hamburg, Germany 
Gilson, Middleton, Germany 
Bio-Rad Laboratories, Inc., Hercules, USA 
Thermo Fisher Scientific, Waltham, MA, USA 
BioRad, Hercules, USA 
Beckman Coulter GmbH, Krefeld, Germany 
Bio-Rad Laboratories, Inc., Hercules, USA 
 
 
 
 
 
2.1.9. Kits 
 
Kit Company 
ABsolute SYBR® Green ROX mix  
 
 
BigDye® Terminator sequencing kit  
Click-iT® EdU proliferation kit (Alexa488)  
Cytokine array - Human cytokine antibody 
DuoLink in situ orange starter kit mouse 
ECL Western Blot detection kit 
EUROTAQ TAQ DNA pol kit 
MagniSort® Human T cell Enrichment Kit 
Plasmid Maxi kit 
Plasmid Mini kit 
Precisor high fidelity DNA polymerase kit  
Thermo Fischer Scientific, Langenselbold, 
Germany  
 
Applied Biosciences, Foster City, USA  
Life Technologies, Darmstadt, Germany  
Abcam, Cambridge, UK 
Sigma-Aldrich, Munich, Germany 
GE Healthcare Europe GmbH, Freiburg, Germany 
EuroClone/Biozol, Eching, Germany   
eBioscience, San Diego, CA, USA 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany  
Biocat, Heidleberg, Germany 
QIAshredder  
QiAquick Gel extraction kit  
QiAquick PCR purification kit 
Rapid DNA ligation kit 
RNeasy Micro kit 
RNeasy Mini kit 
 
Qiagen, Hilden, Germany  
Qiagen, Hilden, Germany  
Qiagen, Hilden, Germany  
Roche, Mannheim, Germany 
Qiagen, Hilden, Germany  
Qiagen, Hilden, Germany  
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2.1.10. Other material  
 
 
Material Distributor 
0.22μm Millex 4mm Durapore PVDF filters 
1.0μm FluoSpheres Biotin-labeled 
Microspheres 
ABgeneTM adhesive PCR plate seals  
Cover slips (24x60 mm) Marienfeld 
Dako Pen  
Eppendorf Safe-Lock microcentrifuge tubes 
(1.5 mL, 2.0 mL) 
Merck Millipore, 
Thermo Fisher Scientific, Waltham, MA, USA 
ABgene, Epsom, UK  
R. Langenbrinck GmbH, Emmendingen, 
Germany 
Dako, Glostrup, Denmark 
Eppendorf, Hamburg, Germany 
FACS tubes 
Falcon® tubes (15 and 50mL) 
BD Bioscience, Heidelberg, Germany  
BD Bioscience, Heidelberg, Germany  
 
Fuji X-ray Film Super RX Kisker Biotech, Steinfurt, Germany 
NuPAGE® antioxidant  
NuPAGE® Bis-Tris precast gels (15 or 10 well; 
1.5 or 1 mm)  
PCR tubes (0.2 ml)  
Pipette tips (10 μl, 20 μl, 100 μl, 200 μl, 1000 
μl)  
Polyvinylidene fluoride (PVDF) membrane  
QIAshredderTM  
X100 syringe luer centre 1mL 
Life Technologies, Darmstadt, Germany  
Life Technologies, Darmstadt, Germany  
 
Molecular BioProducts, San Diego, USA  
Starlab, Ahrensburg, Germany  
 
Sigma Aldrich, Munich, Germany  
Qiagen, Hilden, Germany  
Terumo/Novodirect, Kehl/Rhein, Germany 
 
 
 
 
2.1.11. Plasmids 
 
- pLVX_Puro (Clontech)  
- pGEM-He-Juel (obtained from Holger M. Becker, TU Kaiserslautern, Germany) 
 
See appendix for plasmid maps. 
 
Generated plasmids 
- pLVX_BCAT1-v1 (previously generated by co-workers. In short, for overexpression of 
BCAT1, the insert was generated using PCR and subsequently cloned into the XbaI and 
XhoI sites of the pLVX-puro lentiviral vector (Tönjes et al., 2013). 
- pGEM-He-Juel-BCAT1-v6 
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2.1.12. Primers 
 
Application Gene 
name 
Oligo Name Sequence 5' to 3'  
qRT-PCR 
SLC16A1 
MCT1-F3 TTGTGGAATGCTGTCCTGTC 
MCT1-R3 ACATGTCATTGAGCCGACCT 
SLC16A3 
MCT4-F3 TACCTCACCACTGGGGTCAT 
MCT4-R3 TTCAGCATGATGAGCGAGGG 
SLC16A7 
MCT2 Forw 2 CAAAGACTCTGGGACTCTTGGT 
MCT2 Rev 2 TCTGGAGGTGGATGCACAG 
BCAT1 
BCAT1_h_rt_fwd1 CAACTATGGAGAATGGTCCTAAGCT 
BCAT1_h_rt_rev1 TGTCCAGTCGCTCTCTTCTCTTC 
ARF1 
ARF_h_rt_fwd GACCACGATCCTCTACAAGC 
ARF_h_rt_rev TCCCACACAGTGAAGCTGATG 
TBP 
TBP_h_rt_fwd GAACCACGGCACTGATTTTC 
TBP_h_rt_rev CCCCACCATGTTCTGAATCT 
Cloning 
BCAT1 
BCAT1_v6_h_Bam
HI_fwd 
GATCGGATCCATGGATTGCAGTAACGGAT 
BCAT1_h_HindIII_r
ev 
GATCAAGCTTTCAGGATAGCACAATTGTCC 
 T7 sequencing 
primer 
TAATACGACTCACTATAGGG 
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2.1.13. siRNAs 
 
siRNA target  
siRNA sc45892, Santa Cruz MCT4 
siRNA smart pool M-005126-04-0005, Dharmacon 
siRNA smart pool M-007402-02-0005, Dharmacon 
MCT4 
MCT1 
non-target #2 siRNA pool D-001206-14-05, 
Dharmacon 
 
  
 
2.1.14. Software 
 
Software Company 
Basic Local Alignment Search Tool (BLAST)  
Empower3 software suite  
EndNote X7 
FACS-Diva  
Gene Set Enrichment Analysis (GSEA) 
 
GraphPad Prism 7  
Hokawo 
ImageJ 
ncbi.nlm.nih.gov 
Waters, Eschborn, Germany 
Thomson ResearchSoft, Carlsbad, USA  
BD Biosciences, Heidelberg, Germany 
http://software.broadinstitute.org/gsea/in
dex.jsp  
GraphPad, San Diego, USA  
Hamamatsu Photonics Germany GmbH 
imagej.nih.gov/ij 
Ingenuity® Pathway Analysis  
Primer-BLAST 
SDS 2.4 
 
Qiagen, Hilden, Germany  
ncbi.nlm.nih.gov 
Applied Biosystems, Foster City, USA  
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2.2. Methods  
 
2.2.1. Cell Culture Conditions 
 
Human glioblastoma cell lines 
 
- U87-MG and U251-MG 
Inducible BCAT1 knockdown cells were established as described previously (Tönjes et al., 
2013) by infecting U87-MG and U251-MG cells with pLKO-Tet-On non-target (nt) shRNA and 
pLKO-Tet-On BCAT1 shRNA2 lentiviral particles and selecting with puromycin (1 μg/mL) for 7 
days. Induction was achieved by adding 0.1 μg/mL doxycycline to the medium for at least 3 
days. Cells were cultured in DMEM containing 1 g/L glucose (D5921, Sigma) supplemented with 
10% Tetracycline-free fetal bovine serum (Tet-free FBS), 1% penicillin and streptomycin (P/S) 
mix and glutamine (0.5 mM). Cell lines were cultivated at 37 °C in a humidified incubator with 
10% CO2. 
- LN-229 
Cells were cultured in DMEM containing 4.5 g/L glucose (D5796, Sigma) supplemented with 
10% Fetal calf serum (FCS) and 1%P/S. Cells were cultivated at 37 °C in a humidified incubator 
with 10% CO2. 
 
Monocytic cell lines 
 
- U937  
Cells were cultured in RPMI (1640) supplemented with 10%FCS and 1%P/S. Cells were 
cultivated at 37 °C in a humidified incubator with 5% CO2. Differentiation to macrophages was 
obtained by treatment with 5 nM phorbol 12-myristate 13-acetate (PMA) for 48h.   
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2.2.2. Cell number and viability measurements 
 
The viability and absolute number of cells was determined using a Vi-CELL XR 2.03 cell counter 
(Beckman Coulter). Viability was assessed using trypan blue dye exclusion method and only 
cell suspensions with a viability of at least 90% were used for experiments. 
 
2.2.3. Metabolite quantification using ultra performance liquid chromatography (UPLC) 
 
To quantitatively analyze BCKAs KIV, KIC and KMV, we established protocols for ultra-
performance liquid chromatography (UPLC) separation coupled to fluorescence detection using 
either O-Phenylendiamine (OPD) or 1,2-diamino-4,5-methylendioxybenzene (DMB) as 
derivatization agents. The DMB method was used to quantify intracellular BCKA concentrations 
whereas the OPD method was used to quantify other metabolites, including pyruvate, 
ketobutyrate and glyoxalate (Supplementary table 1) (Appendix). 
For derivatization with OPD (o-phenylendiamine) reagent, 100 µL of cell culture supernatant 
were mixed with 200 µL ice-cold 1M perchloric acid for protein precipitation. After centrifugation 
at 4°C and 16 400 g for 10 min, 150 µL of the supernatant were mixed with an equal volume of 
OPD derivatization solution and  (25 mM OPD in 2M HCl) and derivatized by incubation at 50°C 
for 30 min. After centrifugation for 10 min, the derivatized ketoacids were separated by reversed 
phase chromatography on an Acquity HSS T3 column (100 mm x 2.1 mm, 1.7 µm, Waters) 
connected to an Acquity H-class UPLC system. Prior separation, the column was heated to 
40°C and equilibrated with 5 column volumes of solvent A (0.1% formic acid in 10% acetonitrile) 
at a flow rate of 0.55 mL/min. Separation of ketoacid derivates was achieved by increasing the 
concentration of solvent B (acetonitrile) in solvent A as follows: 2 min 2% B, 5 min 18% B, 5.2 
min 22% B, 9 min 40% B, 9.1min 80% B and hold for 2min, and return to 2% B in 2 min.  
For determination of intracellular BCKA content, cells were extracted with 200 µL cold 1M 
perchloric acid. Insoluble material was removed by centrifugation for 10 min at 25.000g. For  
derivatization with DMB (1,2-diamino-4,5-methylendioxybenzene), 30 µL extract were mixed 
with 30 µL DMB derivatization reagent (5mM DMB, 20mM sodium hydrosulfite, 1M 2-
mercaptoethanol, 1.2M HCl) and incubated at 100°C for 45 min. After 10 min centrifugation, the 
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reaction was diluted with 240 µL 10% acetonitrile. UPLC system, column and solvent was used 
as described above. Baseline separation of DMB derivates was achieved by increasing the 
concentration of acetonitrile (B) in buffer A as follows: 2 min 2% B, 4.5 min 15% B, 10.5 min 
38% B, 10.6 min 90% B, hold for 2 min, and return to 2% B in 3.5 min. 
BCKAs levels in cell lysates and in supernatants from Xenopus oocytes (2.2.7.2) were detected 
using the derivatization with DMB derivatization reagent as described above. 
The separated derivates were detected by fluorescence (Acquity FLR detector, Waters, OPD: 
excitation: 350 nm, emission: 410 nm; DMB: excitation: 367 nm, emission: 446 nm) and 
quantified using ultrapure standards (Sigma). Data acquisition and processing was performed 
with the Empower3 software suite (Waters). 
 
2.2.4. Protein quantification  
 
For protein extraction, cells were washed twice with PBS and resuspended in 40-60μL RIPA-
lysis buffer, which was supplemented with 1X protease and phosphatase inhibitor cocktail (PIC)  
and 1X EDTA. The lysates were centrifuged at 13000 rpm at 4°C for 5 min and the supernatants 
containing the protein extracts were stored at -80°C. Total protein was quantified using 
bicinchoninic acid (BCA) method. Protein samples were diluted either 1:2 or 1:4 in RIPA lysis 
buffer and 1 µL was pipetted into 0.2 µL tube.  Bicinchoninic acid and copper sulphate solution 
mixed in a ratio of 50:1 and 20 μL of this solution was added to each tube. Each sample was 
measured in duplicate and RIPA buffer was used for the blank measurement. Protein-Cu2+ 
complex form during the subsequent incubation at 37°C for 30 min with consequent reduction of 
Cu2+ to Cu1+ by protein in an alkaline environment containing sodium potassium tartrate. BCA 
reacts with the reduced cation forming a purple-colored complex, the absorption of which was 
measured at 562 nm. A bovine serum albumin (BSA) based standard curve was used for 
regression analysis to determine protein concentration. 
 
2.2.5. Western blot 
 
Total protein of cell lines was extracted using RIPA lysis buffer (as described in section 2.2.4). 
15 µg of protein was separated by 4-12% SDS-PAGE and transferred to a polyvinylidene 
difluoride membrane. The membrane was blocked in blocking solution (5% Milk in TBS-T) and 
incubated with primary antibodies overnight at 4°C. Horseradish peroxidase (HRP)-conjugated 
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secondary antibodies were incubated for 1h at room temperature (RT) before chemiluminescent 
detection of protein (ECL kit, GE Healthcare). The following antibodies were used: monoclonal 
mouse antibody to α-tubulin (1:3000 dilution) (clone DM1A, #T9026, Sigma-Aldrich), anti-MCT4 
(sc50329, Santa Cruz) antibody (1:1000 dilution), anti-MCT1 (AB3538P, Millipore) (1:500 
dilution), anti-MCT2 (PA5-50518, Thermo Fisher Scientific) (1:1000 dilution). HRP-conjugated 
antibody to mouse IgG (1:5000 dilution) (sc-2005, Santa Cruz) or HRP-conjugated antibody to 
rabbit IgG (1:3000 dilution) (sc-2004, Santa Cruz) were used as secondary antibodies. 
2.2.6. RNA extraction, RT-PCR and qPCR 
 
RNA extraction 
Total RNA was isolated using RNeasy Microkit, Qiagen according to the manufacturer’s 
instructions. RNA concentration was measured using Nanodrop ND-1000 spectrophotometer. 
In the preparation of RNA for microarray analysis, cells were lysed in 350 μL RLT buffer 
(RNeasy Microkit, Qiagen) and the lysate was homogenized by passing through QiashredderTM 
columns at 13000 rpm for 2 min at RT. DNAse I on column treatment step was performed.  
 
RT-PCR 
Total RNA was reverse transcribed using random primers and Superscript II Reverse 
Transcriptase according to manufacturer’s instructions. In short, first, residual DNA was 
removed by incubation of total RNA with 1 μL DNAse I and 2 μL first strand buffer for 15 min at 
RT. Samples were then incubated with a random primer mix for 10 min at 65°C and 2 min at RT 
for primer hybridization. Finally, 1 μL Superscript II Reverse Transcriptase was added and 
incubation at 42°C for 50 min followed. The reaction was stopped by incubation at 94°C for 10 
min. ddH2O was added to achieve a final cDNA concentration of 16.67 ng/μL. 
 
Quantitative Real Time PCR (qPCR) 
Each cDNA sample was analyzed in triplicate with the Applied Biosystems Prism 7900HT Fast 
Real-Time PCR System using Absolute SYBR Green ROX Mix. Primers were also tested on 
genomic DNA and ddH2O. The relative amount of specific mRNA was normalized to ARF1 and 
TBP mRNA. Primer sequences are given in 2.1.12. 
 
The following amplification protocol was used, with 40 cycles of steps 2 and 3: 
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Step Temperature (°C) Time 
1: activation 50 2 min 
2: initial denaturation 95 15 min 
3: denaturation 95 15 sec 
4: annealing/extension 60 1 min 
   
 
Data was analyzed using the SDS 2.4 software. For relative quantification, mean ratios were 
calculated between the gene of interest and two housekeeping genes (ARF1 [ADP-ribosylation 
factor 1] and TBP [TATA-box binding protein]). 
2.2.7. Heterologous expression of BCAT1 and MCTs in Xenopus oocytes  
 
2.2.7.1. Cloning of human BCAT1-v6 into pGEM-He-Juel vector 
 
BCAT1-version 1 (v1) was previously cloned into pLVX_Puro vector (Tönjes et al., 2013) and 
this vector was used to subclone human BCAT1-version 6 (v6) into the oocyte expression 
vector pGEM-He-Juel. 
PCR using pLVX_BCAT1-v1 vector and BCAT1_v6_h_BamHI forward primer and 
BCAT1_h_HindIII reverse primer (2.1.12) using the following reaction mix: 
PCR reaction Mix 
Reagent Volume (μL) 
HiFi buffer 5X (Biocat) 30 
pLVX-BCAT1-v1 (0.01μg/μl) 0.5 
dNTPs Mix (Biocat) 1.5 
primer BCAT1_v6_h_BamHI_fwd (10μM) 3 
primer BCAT1_h_HindIII_rev (10μM) 3 
PRECISOR High-fidelity DNA polymerase (Biocat) 3 
ddH2O 109 
Total 150  
 
PCR program 
Temperature (°C) Time Cycles 
98 30 sec  
98 30 sec 
35 66 30 sec 
72 45 sec 
72 10 min  
4 ∞  
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5 μL of PCR product were analyzed by 1% agarose gel electrophoresis and the remaining 
volume was purified using QiAquick PCR purification Kit (Qiagen) accordingly to manufacturer’s 
protocol. After purification, PCR product was digested at 37°C 30 min followed by 80°C 10 min 
using BamHI Fast digest (FD) and HindIII Fast digest (FD) restriction enzymes as follows: 
Digestion reaction 
 BCAT1-v6 PCR product pGEM-He-Juel pGEM-He-Juel 
 Volume (μL) Volume (μL) Volume (μL)   
DNA 
BamHI FD 
48 
3 
1 
1 
1 
- 
HindIII FD 3 1 - 
FD green buffer (10X) 6 2 2 
ddH2O - 15 17 
Total  60 60 60 
 
Digestion products were analyzed by 1% agarose gel electrophoresis and agarose bands were 
excised from the gel and DNA was extracted using QiAquick Gel extraction kit (Qiagen) 
accordingly to manufacturer’s protocol. DNA was quantified using Nanodrop ND-1000 
spectrophotometer and ligation reaction was performed at RT for 15 min using Rapid DNA 
ligation kit (Roche) as follows: 
Ligation reaction 
 pGEM-He-Juel BCAT1-v6 
 Volume (μL) Volume (μL) 
DNA (final concentration 50ng/μL) 3 1 
1X Dilution buffer (Roche) 6 
10 
1 
T4 DNA ligase buffer (Roche) 
T4 DNA ligase (Roche) 
Total  21  
   
5 μL of ligation reaction were added to 50 μL of TOP10 E.coli (Life Technologies) and 
transformation was performed as follows: 30 min incubation on ice, 30 sec at 42°C followed by 2 
min incubation on ice. 250 μL S.O.C. medium (Thermo Fisher Scientific) were added and cells 
were incubated 1h at 37°C with agitation (300 rpm). After incubation time 50 μL were plated in 
Agar plates with ampicillin and incubated ON at 37°C. On the next day, 10 colonies were 
selected and picked from the agar plates and colony PCR was performed using the following 
conditions: 
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Colony PCR Mix 
Reagent Volume (μL) 
10X PCR buffer (EUROTAQ kit) 2.5 
dNTPs Mix 0.25 
MgCl2 0.75 
primer BCAT1_v6_h_BamHI_fwd (10μM) 0.5 
primer BCAT1_h_HindIII_rev (10μM) 0.5 
EUROTAQ DNA polymerase 0.25 
ddH2O 20.25 
Total 25 
 
PCR program 
Temperature (°C) Time Cycles 
98 30 sec  
98 30 sec 
35 66 30 sec 
72 45 sec 
72 10 min  
4 ∞  
   
 
PCR product was analyzed using 1% agarose gel electrophoresis. The colonies containing the 
BCAT1-v6 insert were used for small scale plasmid preparation. 3 mL LB medium containing 
ampicillin were inoculated with a pipette tip containing a picked bacterial colony and incubated 
overnight at 37°C with shaking. Plasmid isolation followed using a QIAprep® spin Minikit  
(Qiagen) according to the manufacturers’ protocol. Concentrations were determined using a 
NanoDrop ND-1000 spectrophotometer. 
The sequences of pGEM-He-Juel-BCAT1-v6 plasmid was verified by Sanger sequencing using 
a BigDye® Terminator v3.1 Cycle sequencing kit. 2 μL T7 sequencing primer (2.1.12) (10μM) or 
2 μL BCAT1_h_HindIII reverse primer (10 μM) (2.1.12), 1 μL BigDye® terminator mix, 2 μL 5X 
sequencing buffer were added to 300 ng of plasmid DNA (1.2 μL) and ddH2O up to 21 μL. PCR 
sequencing was performed accordingly to the table below:  
PCR program 
Temperature (°C) Time Cycles 
96 3 min  
96 30 sec 
25 51 15 sec 
60 4 min 
4 ∞  
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PCR products were purified by precipitation with 27.5 μL absolute ethanol and 1.1 μL 3M 
sodium acetate, with subsequent centrifugation at 13000 rpm 30 min at RT. The precipitated 
pellet was washed with 100 μL 60% ethanol and centrifuged at 13000 rpm 14 min. The 
precipitated pellet was dried at 37°C and dissolved in 11 μL formamid. Sequencing was 
performed using ABI PRISM 3100 genetic analyzer.  
After confirming the sequence of the plasmid, large scale plasmid preparation was performed by 
inoculating 300 mL LB medium supplemented with ampicillin with E.coli (transformed with the 
pGEM-He-Juel-BCAT1-v6 plasmid) glycerol stocks and incubated at 37°C ON with agitation 
(200 rpm). For plasmid isolation the Qiagen Maxiprep Kit was used according to the 
manufacturers’ protocol. Concentrations were determined using a NanoDrop ND-1000 
spectrophotometer. 
2.2.7.2. Heterologous protein expression in Xenopus oocytes  
 
The generated pGEM-He-Juel-BCAT1-v6 plasmid was sent to Holger Becker for following 
heterologous expression of human BCAT1 in the Xenopus oocytes. In addition, plasmid DNA of 
MCT1, MCT4 or NBCe1 cloned into pGEM-He-Juel, which contains the 5’ and the 3’ 
untranscribed regions of the Xenopus β-globin flanking the multiple cloning site, was used. DNA 
was linearized with SalI and transcribed in vitro with T7 RNA-polymerase (mMessage 
mMachine, Ambion Inc., USA) as described earlier (Becker et al., 2004).  
Oocytes at stages V were injected with 5 ng of cRNA coding for rat MCT1 or rat MCT4, 12 ng of 
cRNA coding for human BCAT1, 7 ng cRNA coding for human NBCe1, 5 ng of cRNA for rat 
MCT1 or MCT4 and 12 ng of cRNA for human BCAT1 5 days before the experiments. 
Native oocytes or oocytes expressing the specified proteins were stimulated with BCAAs (1 
nmol L-Valin, 1 nmol L-Leucin, 1 nmol L-Isoleucin) and α-ketoglutarate (3 nmol) for 2h at RT. 
After the incubation time, culture medium was removed and stored for posterior analysis by 
UPLC (2.2.3) and cells were lysed by pipetting and the lysate was centrifuged for 10 min at 10 
000 g at 4°C and stored before analysis by UPLC (2.2.3). 
Batches of 10 oocytes were used per condition and the experiment was performed 3 times. 
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2.2.8 MCT1 inhibition  
 
A total of 1 x 105 U87nt or U87shBCAT1, U251nt or U251shBCAT1 and 0.4 x 105 LN-229 cells 
were seeded onto 12-well plates, medium was replaced after 16 hours and fresh medium with 
AR-C155858 (Tocris) or DMSO was added and cells were incubated at 37°C 10%CO2 for 24 
hours. U87 and LN-229 cells were treated with 1 µM AR-C155858 whereas for U251 cells 2 µM 
AR-C155858 was used. Supernatants from U87nt, U87shBCAT1, U251nt, U251shBCAT1 and 
LN-229 cells treated with MCT1 inhibitor (AR-C155858) or DMSO were centrifuged at 2000 rpm 
for 5 min and filtered using 0.22μm filters and analyzed by UPLC. Cells were harvested by 
trypsinization, centrifuged at 1000 rpm for 5 min and washed once with ice-cold 0.9% NaCl, and 
the cells pellets were frozen at -80°C before analysis by UPLC (2.2.3). 
 
2.2.9 Cell proliferation analysis 
 
To assess the effect of MCT1 inhibitor (AR-C155858, Tocris) on proliferation of glioblastoma 
cells the Click-iT EdU cell proliferation assay (Invitrogen) was used following the manufacturer’s 
instructions. The cells were incubated with 10 μM of the nucleoside analog EdU for 8-10h. 
Quantification of cells that incorporated EdU was performed using a FACS Canto II (BD 
Biosciences). 
 
2.2.10 MCT4 and MCT1 siRNA mediated knockdown  
 
A total of 2.5 x 105 U87nt, U251nt or LN-229 cells were seeded onto 6-well plates in medium 
without P/S and incubated at 37°C 10%CO2 ON. Cells were transfected using DharmaFECT 1 
transfection reagent (Dharmacon) with 25nmol of MCT4 siRNA (sc45892, Santa Cruz) (siMCT4 
1), MCT4 siRNA smart pool (M-005126-04-0005, Dharmacon) (siMCT4 2), 25nmol of MCT1 
siRNA (M-007402-02-0005, Dharmacon) or non-target (nt) #2 siRNA pool (D-001206-14-05, 
Dharmacon). Control cells were incubated with Opti-MEM medium (Gibco) and DharmaFECT1 
(no siRNA added). Cells were incubated at 37°C 10%CO2 for 48h with medium change at 24h 
post transfection. At 48h post transfection, cells were harvested for RNA isolation (RNeasy 
Microkit, Qiagen) and protein extraction (using RIPA buffer) and the knockdown efficiency was 
evaluated by qPCR (2.2.6) and western-blot (2.2.5). Supernatants from U87nt or U251nt cells 
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48h post transfection using non target siRNA or MCT4 siRNAs were centrifuged at 2000 rpm for 
5 min and filtered using 0.22 μm filters and analyzed by UPLC for BCKAs determination (2.2.3).  
 
2.2.11 In situ proximity ligation assay (PLA) 
 
In situ PLA was performed in the U87nt and U251nt cells using the Duolink in situ proximity 
ligation assay (Olink Bioscience, Uppsala, Sweden) accordingly to manufacturer’s protocol. 
In short, cells were seeded onto 8-well chamber slides (Lab-TekII, Thermo Scientific Nunc) and 
incubated ON at 37°C 10%CO2. Cells were fixed with 4% paraformaldehyde solution for 15 min 
at RT, permeabilized with PBS 0.1% TritonX100 for 15 min at RT and dehydrated using a 
ethanol series (70%, 85%, 100%) for 2 min at RT. Before the blocking step cells were 
rehydrated with PBS1X for 15 min at RT. Blocking solution (Olink Bioscience) was added and 
slides were incubated for 30 min at 37°C. The primary antibodies used were anti-BCAT1 (rabbit 
polyclonal antibody, Insight Biotechnology limited (Wembley, UK)) (provided by Myra Conway), 
anti-MCT1 (ab90582, Abcam), anti-MCT4 (376140, Santa Cruz) at 1:100 dilution in Antibody 
diluent (Olink Bioscience) and anti-PGK1 antibody (GTX107614, GeneTex) was used at 1:200 
dilution. Cells incubated without primary antibodies or with only one of each of the antibodies 
tested in combination were used as procedure controls. The results were visualized using 
Axioplan 2 imaging (Zeiss) microscope and Hokawo software. The images were processed and 
PLA signals/cell were quantified using ImageJ software.  
 
2.2.12 Tumor conditioned medium generation 
2.2.12.1 Human serum cultures 
 
A total of 0.3 x 106 U87nt and a total of 0.6 x 106 U87shBCAT1 cells were seeded onto 6-well 
plates in DMEM (D5921, Sigma) supplemented with 10% Human Serum (HS), type AB (MP 
Biomedicals) 1%P/S and glutamine (0.5 mM) with doxycycline (0.1 μg/mL) and incubated for 
96h at 37°C 10%CO2 with medium change at 48h. After 96 hours culture medium was 
harvested and centrifuged at 1200 rpm 10 min at RT and 3000 rpm 10 min at RT and stored at -
80°C. Cells were harvested for RNA extraction (RNeasy Microkit, Qiagen) and cell number was 
determined using Vi-cell Counter (Beckman Coulter). Tumor conditioned medium (TCM) from 
three independent collections was pooled immediately before use. 
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2.2.12.2 No human serum cultures 
 
U87nt or U87shBCAT1 cells after doxycycline induction for at least 3 days were cultured in 
DMEM (D5921, Sigma) supplemented with 10% Tet-free FBS, 1%P/S and glutamine (0.5 mM) 
with doxycycline (0.1 μg/mL) for 2-3 days. Supernatants were then harvested and centrifuged at 
1200 rpm 10 min at RT and 3000 rpm 10 min at RT and stored at -80°C before use. Cells were 
harvested for RNA extraction (RNeasy Microkit, Qiagen) to confirm BCAT1 knockdown 
efficiency. 
 
2.2.13 Isolation of peripheral blood mononuclear cells (PBMCs) from buffy coats 
 
Human PBMCs were isolated from buffy coats from normal donors obtained from the Institut für 
Klinische Transfusionsmedizin und Zelltherapie (IKTZ) (Heidelberg, Germany) by density 
gradient using via Ficoll density separation. In short, 15 mL Biocoll (Biochrom) separation 
solution was applied to Leucosep™ tubes, which were centrifuged at 2000 rpm for 5 min. Blood 
buffy coat samples were diluted 1:3 in PBS and transferred to Leucosep™ tubes, adding 30 mL 
per tube to obtain a total volume of 45 mL. Samples were centrifuged at 2200 rpm for 20 min at 
RT without break.  Four layers were obtained (from top to bottom): plasma layer, PBMC 
interphase, Biocoll layer and erythrocyte/granulocyte pellet. Using a pipet, the PBMC interphase 
was carefully transferred to a new 50 mL Falcon tube, avoiding excess transfer of plasma and 
Biocoll solution. PBMCs were washed twice in PBS and centrifuged at 1200 rpm for 10 min, 
prior to resuspension in RPMI 1640 and cell counting using Vi-cell counter. Assuming that 10% 
of PBMCs are monocytes, respective cell numbers, as needed for downstream experiments, 
were applied to further either positive selection of CD14+ monocytes or enrichment of monocyte 
population by plastic adhesion. 
 
2.2.13.1 Isolation of monocytes from PBMCs isolated from buffy coats 
   
CD14+ magnetic sorting 
 
CD14+ monocytes were purified from healthy donors’ mononuclear cells by CD14 microbeads 
magnetic cell sorting, according to the manufacturer’s instructions (Miltenyi Biotec). In brief, 
cells were centrifuged at 1200 rpm 10 min and resuspended in ice-cold MACS buffer (80 μL per 
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1 x 107 cells) and CD14 MicroBeads (20 μL per 1 x 107 cells). Samples were incubated at 4°C 
for 15 min, prior to additional washing with MACS buffer and centrifugation at 1200 rpm for 10 
min.  Cells were resuspended in ice-cold MACS buffer (108 cells in 500 μL of buffer) and applied 
to LS MACS columns previously equilibrated with ice-cold MACS buffer. Flow through was 
discarded and magnetic columns were washed 3 times with ice-cold MACS buffer. CD14+ 
monocytes were eluted in 5 mL ice-cold MACS buffer and column-based purification was 
repeated one additional time. Subsequently monocytes were counted and resuspended in RPMI 
1640 before cell counting using Vi-cell counter. Purity of the cells was accessed by FACS Canto 
II (BD Biosciences) using anti-CD14 FITC antibody and it was 95–99%. Cellular debris and 
dead cells were excluded from the analysis based on scatter signals.  
 
Enrichment by plastic adhesion 
 
Monocytes were enriched from the PBMCs by plastic adhesion for 2h at 37°C 5%CO2. PBMCs 
were plated in 6-well plates (2x107 cells/mL) in RPMI and incubated for 2h at 37°C 5%CO2. 
After incubation, cells were washed two times with PBS and fresh medium was added to cells 
and incubated ON at 37°C 5%CO2. On the next day, cells were washed with PBS and fresh 
medium was added.  For M-CSF differentiation, DMEM 5796 supplemented with 10%FCS and 
1%P/S was used and M-CSF was added at a final concentration of 20 ng/mL for 7-10 days with 
supplementation every 2 days.  
 
2.2.14 Microarray analysis  
 
Tumor conditioned medium (TCM) differentiated macrophages 
 
CD14 sorted monocytes were plated in 6-well plates (1.5x106 cells/mL) using RPMI and 
incubated for 2h at 37°C 5%CO2. After incubation, medium was removed and DMEM 5921 
supplemented with 10%HS 1%P/S and glutamine (0.5 mM) or TCM supplemented with 10%HS 
was added to cells and incubated at 37°C 10%CO2. At day 4 ½ of fresh medium or TCM 
supplemented with 10%HS was added to the cells. At day 7 medium was changed and fresh 
medium or TCM supplemented with 10%HS was added to the cells. At day 11 cells were lysed 
using RLT buffer (RNeasy Minikit, Qiagen) and transferred to QiAschreder columns (Qiagen) 
and centrifuged at 13000rpm for 2min. RNA was extracted using RNeasy Minikit, Qiagen 
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following manufacturers’ instructions. RNA was hybridized in Illumina HumanHT-12 Chip by the 
Genomics and Proteomics Core Facility (GPCF) at DKFZ, Heidelberg, Germany. Monocytes 
were isolated from four different donors.   
M-CSF differentiated macrophages exposed to BCKAs 
 
Monocyte-derived macrophages differentiated M-CSF during 7 days and treated with 300 µM 
BCKAs (KIV, KIC, KMV) or without BCKAs for 24h at 37°C 10%CO2. After treatment, RNA was 
extracted from cells using RNeasy Mini Kit according to the manufacturer’s protocol. RNA was 
hybridized in Illumina HumanHT-12 Chip by the GPCF at DKFZ, Heidelberg, Germany. 
Monocytes were isolated from four different donors. 
U87 cells expressing normal and low BCAT1 levels  
 
U87nt and U87shBCAT1 cells were grown in the presence of medium supplemented with 
10%HS and doxycycline (2.2.12.1) and RNA was extracted using RNeasy Mini Kit according to 
the manufacturer’s protocol. RNA was hybridized in Illumina HumanHT-12 Chip by the 
Genomics and Proteomics core facility (GPCF) at DKFZ, Heidelberg, Germany. 
2.2.15. BCKAs uptake studies in monocyte-derived macrophages 
 
Monocytes were isolated from the PBMCs and enriched by plastic adhesion ( 2.2.13.1) for 2h at 
37°C 5%CO2 and differentiated either in the presence of U87nt TCM or U87shBCAT1 TCM 
supplemented with 10% HS for 11 days or with 20 ng/mL human M-CSF for 7 days. For TCM 
differentiated macrophages, after differentiation, medium was replaced by  DMEM 5921 10%HS  
1%P/S and glutamine (0.5 mM) with 100 μM or 300 μM KIV, KIC and KMV and cells were 
incubated for 24h at 37°C 10%CO2. For M-CSF differentiated macrophages, after differentiation, 
medium was replaced by DMEM 6046 10%FCS 1%P/S with 100 μM or 300 μM KIV, KIC and 
KMV and cells were incubated for 24h at 37°C 10%CO2. After 24h incubation supernatants 
were collected, centrifuged at 2000 rpm for 5 min, filtered using 0.22 μm filters and analyzed by 
UPLC (2.2.3). Monocytes were isolated from two different donors.  
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2.2.16. 13C-BCKA tracing experiments in monocyte-derived macrophages 
 
Monocytes were isolated from the PBMCs and enriched by plastic adhesion for 2h at 37°C 
5%CO2 and differentiated either in the presence of U87nt TCM or U87shBCAT1 TCM 
supplemented with 10%HS for 12 days or in the presence of 20 ng/mL human M-CSF for 7-10 
days. After differentiation, medium was replaced by DMEM 5921 1%HS 1%P/S and glutamine 
(0.5 mM) with 100 μM or 300 μM 13C α-KIV (13C5, 98%, Cambridge Isotope Laboratories) and 
100 μM or 300 μM 13C α-KIC (1,2-13C2, 99%, Cambridge Isotope Laboratories)  and cells were 
incubated for 48h at 37°C 10%CO2. After 48h cells were collected and intracellular metabolites 
were extracted for Gas Chromatography-Mass Spectrometry (GC-MS) analysis. From M-CSF- 
differentiated macrophages, cell culture medium was also harvested and analyzed using GC-
MS. Monocytes were isolated from two different donors.  
 
2.2.17. Extraction of intracellular metabolites for Gas Chromatography-Mass 
Spectrometry (GC-MS) 
 
Extraction of intracellular metabolites for GC-MS was according to Sapcariu et al, 2014 
(Sapcariu et al., 2014). Briefly, cells were cultivated in 6-well plates, medium was retained for 
quantification of extracellular metabolites and cells washed with 2 mL of 0.9% NaCl. Then 
quenched with 0.2 mL of -20°C methanol and after adding an equal volume of 4°C cold water, 
cells were collected with a cell scraper and transferred to tubes containing 0.2 mL -20°C 
chloroform. The extracts were shaken at 1400 rpm for 20 min at 4°C and centrifuged at 16 000 
g for 5 min at 4°C. 0.2mL of the upper aqueous (polar) phase was collected and stored at -
80°C. After collecting polar phase the non-polar phase was also collected. Interphase was 
washed with 0.3 mL -20°C methanol and centrifuged at 16 000 g for 10 min at 4°C. After 
removing the methanol, 50 μL of methanol were added and interphase was stored at -80°C. 
Polar phase was subsequently subjected to GC-MS analysis. 
Extraction of metabolites from cell culture medium was according to Sapcariu et al, 2014. 
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2.2.18. Gas chromatography-mass spectrometry (GC-MS) 
 
Derivatization was performed with a Gerstel autosampler directly before measurement on the 
GC-MS. Dried metabolites were dissolved in 15 µL of 2% methoxyamine hydrochloride in 
pyridine at a temperature of 40°C for 60 min. Then, 15 µL of 2,2,2-trifluoro-N-methyl-N-
trimethylsilyl-acetamide + 1% chloro-trimethyl-silane was added and incubated at 40°C for 30 
min. The metabolite extracts were measured on an Agilent 7890 GC containing 
with a 30 m DB-35MS capillary column. The GC was connected to an Agilent 5975C MS 
operating in electron ionization (EI) at 70 eV. 1µL of derivatized sample was hot injected at 
270°C in splitless mode. Helium was used as the carrier gas at a flow rate of 1 mL=min. The GC 
oven temperature was kept constant at 100°C for 2 min and then increased to 300°C at 
10°C/min, where it was held for 4 min. The total GC-MS run time of one sample was 26 min. For 
relative quantification of metabolite levels, an alkane mix was run with the experimental 
sequence in order to provide retention index calibration for the experimental samples. The MS 
source was kept at a constant temperature of 230°C and the quadrupole 
at 150°C. For relative quantification of metabolite levels, the detector was operated in scan 
mode with an m/z range of 70 to 800. For analysis of stable isotope labeling, the detector was 
operated in selected ion monitoring (SIM) mode. Relative abundance of each mass isotopomer 
(M) was determined using mass isotopomer distribution analysis.  
 
2.2.19. Phagocytosis assay 
 
Monocyte-derived macrophages differentiated in the presence of 20 ng/mL human M-CSF 
(Miltenyi Biotec) (2.2.13.1) previously incubated in the absence or presence of 300 μM BCKAs 
(KIV, KIC, KMV) at 37°C for 24h were incubated with 1 μm diameter fluorescent biotin-labeled 
beads (F8768, Molecular probes, Life technologies) at a ratio of 50 beads/cell at 37°C for 2h. 
After 2h, medium was removed and cells were washed 5X with 1X PBS and cells were stained 
with Cell Mask stain (Molecular probes, Life Technologies) for 10min at 37°C prior to fixation in 
4% paraformaldehyde for 20 min at RT. In parallel cells were stained with Streptavidin 
Phycoerythrin (PE) (554061, BD Biosciences) at 1:200 dilution for 30 min at 4°C prior to fixation 
in 4% paraformaldehyde for 20 min at RT. Hoechst dye (Molecular probes, Invitrogen) was used 
to stain cell nuclei. Phagocytosis of fluorescent beads was examined by fluorescence 
microscopy (Cell Observer, Zeiss). The number of beads engulfed by each cell was quantified 
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using ImageJ software. Cells were isolated from two different donors and 3-4 fields per 
condition were examined. 
2.2.20. Differentiation of macrophages using U87 TCM  
 
Primary cells 
 
Macrophages were differentiated from monocytes isolated from PBMCs via enrichment by 
plastic adhesion (2.2.13.1) using U87nt/U87shBCAT1 TCM (2.2.12.2) or medium supplemented 
with M-CSF for 7 days. After differentiation, photos were taken using Leica DM IRBE 
microscope.  
U937 model 
 
U937 cells  (10x105 cells/mL) were plated in 6-well plates and differentiated in the presence of 5 
nM PMA either in DMEM 5921 10%Tet-free FBS 1% P/S and glutamine (0.5 mM) or U87nt/ 
U87shBCAT1 TCM (2.2.12.2) for 48h. After 48h, cells were harvested by incubation with 
accutase during 20 min at RT and cell number was determined using Vi-cell counter.  
 
2.2.21. Cytokine array U87 TCM 
 
Supernatants collected from U87nt or U87shBCAT1 cells cultured in the presence of 10%HS 
(TCM) (2.2.12.1) were collected and human cytokine antibody array (ab133998, Abcam) was 
performed accordingly to manufacturer’s instructions. In short, membrane was blocked using 1X 
blocking buffer at RT for 30 min and incubated with 2 mL TCM at 4°C ON under gentle agitation 
followed by washing steps with Wash buffer 1 and 2. Next, membrane was incubated with 1mL 
1X Biotin-Conjugated anti-cytokines for 2h at RT. Washing steps with Wash buffer 1 and 2 were 
performed before incubation with 2 mL of 1X HRP-Conjugated Streptavidin for 2h at RT. 
Membrane was washed once more before chemiluminescence detection using Fusion solo S 
(Vilber Lourmat) equipment. 
2.2.22. Monocyte migration in vitro assay   
 
Monocyte migration was assessed in transwell migration assays using 24-well transwell inserts 
with 5 μm pore size. Monocytes were isolated from PBMCs by CD14+ magnetic sorting 
(2.2.13.1) (purity >94%) and 5.5x106 cells/mL were resuspended in DMEM 5921 10%HS and 
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seeded in the upper wells. The lower chamber contained U87nt/U87shBCAT1 TCM (2.2.12.1) 
or 200 ng/mL CCL2 in DMEM as a positive control. The cells were allowed to migrate for 2h at 
37°C. After incubation, upper culture inserts were carefully removed and cells migrated to 
bottom chambers were harvested and counted using Vi-cell counter. Monocytes were isolated 
from two different donors. 
 
2.2.23. T cell proliferation assay  
 
To further investigate the impact of BCAT1 knockdown in the tumor cells on T cell proliferation 
we used tumor conditioned medium collected from U87-MG cells expressing normal (nt) or 
reduced BCAT1 (shBCAT1) levels (2.2.12.1) and performed a T cell proliferation assay. PBMCs 
were isolated from the blood via Ficoll density separation (2.2.13) and T cells were isolated by 
negative selection using MagniSort® Human T cell Enrichment Kit (eBioscience) accordingly to 
manufacturer’s protocol. After total T cell harvest, CD4+ T-helper cells were separated from the 
rest with the MACS human CD4 Microbeads (Miltenyi Biotec) accordingly to manufacturer’s 
protocol. CD8+ population was stained with CFSE (Life Technologies) and staining efficiency 
was verified by FACS. 300 000 CD8+ T cells were seeded in each well of 96-well plate and 125 
μL of tumor conditioned medium was added per well. Cells were then stimulated with IL-2 and 
PHA and incubated at 37°C for 6 days. At the end of incubation, FACS analysis for CFSE 
staining using FACS Canto II instrument was performed. Average mean fluorescent intensity 
(MFI) and percentage of proliferating cells were calculated.  
 
 
2.2.24. Statistical analysis  
 
Statistical analysis was performed using GraphPad Prism software. Differences in means as 
determined by Student’s t-test or Mann-Whitney test was considered statistically significant at 
p<0.05. Furthermore, the following convention was used: *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001.  
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3. Results 
3.1. MCT1-mediated excretion of glioblastoma cell branched-chain 
ketoacids modulates macrophage phagocytosis 1  
3.1.1. Glioblastoma cells excrete BCKAs 
 
To quantify the content of the branched chain ketoacids α-ketoisocaproate (KIC), 
α-ketoisovalerate (KIV) and α-keto-methylvalerate (KMV) in biologic extracts, an ultra-
performance liquid chromatography (UPLC) protocol in which ketoacids were derivatized with 
either O-Phenylendiamine (OPD) or 1,2-diamino-4,5-methylendioxybenzene (DMB) was 
established. While the very sensitive DMB method allows for the analysis of the usually low 
intracellular BCKA concentrations, the less sensitive OPD method was used to quantify the 
levels of BCKAs and pyruvate in cell culture supernatants (Figure 7A and B). Analysis of cell 
culture media from three glioblastoma cell lines, U87-MG, U251-MG and LN-229, revealed 
accumulation of BCKAs to concentrations of up to 85 µM over a period of 24 hours (Figure 7C) 
indicating that glioblastoma cells are producing and excreting large amounts of BCKAs. To 
further support our observation, we performed shRNA-mediated knockdown in two cell lines of 
the metabolic enzyme BCAT1 (Figure 7D), which generates BCKAs by transamination of 
BCAAs in the cytoplasm. BCAT1 knockdown resulted in reduction of BCKAs excretion of about 
70% and 50% in U87-MG and U251-MG, respectively (Figure 7E and F). These data identify 
BCAT1 as the predominant source of BCKAs excreted by glioblastoma cells. 
 
 
                                               
1
 This chapter is the subject of a manuscript entitled “MCT1-mediated excretion of glioblastoma cell branched-chain ketoacids 
modulates macrophage phagocytosis” which is currently submitted at EMBO Reports, and of which I am the first author and has 
been originally written by myself.   
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(Figure legend on the next page) 
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Figure 7 – Glioblastoma cells excrete BCKAs.  
BCKAs (KIV, KIC, KMV) are detected by Ultra Performance Liquid Chromatography (UPLC) coupled to 
fluorescence detection in cell extracts using the derivatization with DMB (A) or in cell culture supernatants using the 
OPD derivatization reagent (B). (C) BCKAs (KIV, KIC, KMV) levels (μM) detected in supernatants from U87-MG 
and U251-MG cells expressing normal BCAT1 levels, U87nt and U251nt, respectively, and from LN-229 cells. (D) 
BCAT1 mRNA expression in U87-MG and U251-MG cells after BCAT1 knockdown. Expression levels are 
normalized to those from cells expressing normal BCAT1 levels (nt: non-target). Values are mean ± SD of three 
technical replicates. BCKAs levels after BCAT1 knockdown in supernatants from U87 (E) and U251 (F) cells. 
Values are mean ± SD of three technical replicates. (E) and (F) BCKAs levels are normalized to the detected levels 
in U87nt or U251nt cells, respectively. Data generated with support of Dr. Gernot Poschet, COS, University of 
Heidelberg, Heidelberg, Germany. KIV: α-ketoisovalerate. KIC: α-ketoisocaproate. KMV: α-keto-β-methylvalerate. 
unpaired t-test; * p<0.05 ** p<0.01 *** p<0.001 
3.1.2. MCTs expression in glioblastoma 
 
To determine which of the monocarboxylate transporters could be responsible for BCKA 
excretion from glioblastoma cells, we analyzed their RNA expression in published data of 
primary untreated glioblastoma (n=480; TCGA dataset). SLC16A1 (MCT1) and SLC16A3 
(MCT4) both were significantly overexpressed in glioblastoma compared to normal brain (NB) 
tissue (Figure 8A). SLC16A7 (MCT2) and SLC16A8 (MCT3) expression were variable but on 
average lower in tumor than in normal tissue (Figure 8A). Comparing glioblastoma subtypes, 
MCT4 expression was significantly higher in mesenchymal tumors than in others (Figure 8B). 
Expression of MCT1 and MCT4 on RNA (Figure 8C) and protein (Figure 8D) levels was 
confirmed in three glioblastoma cell lines, U87-MG, U251-MG and LN-229, which commonly are 
used as in vitro models. 
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Figure 8 – MCT1 and MCT4 are upregulated in glioblastoma.  
mRNA expression of SLC16A1 (MCT1), SLC16A3 (MCT4), SLC16A7 (MCT2), SLC16A8 (MCT3) in glioblastoma (GB 
IDHwt) (n=480) compared to normal brain (NB) tissue (n=9) in samples from the TCGA dataset (A). (B) mRNA 
expression of SLC16A3 in the four different subtypes of glioblastoma (n=480) defined by gene expression patterns 
compared to normal brain (NB) tissue (n=9) in samples from the TCGA dataset. Values are mean ± SEM. unpaired t-
test  * p< 0.05; ** p< 0.01 *** p< 0.001; **** p< 0.0001. Expression of MCT1 and MCT4 in the glioblastoma cell lines 
U87nt (nt: non-target), U251nt (nt: non-target) and LN-229, at mRNA (C) and protein level (D).  (C) Values are mean 
±SD and are normalized to the levels detected for U87nt. (D) α-tubulin was used as loading control. 
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3.1.3. MCT1 and MCT4 transport BCKAs across cell membranes 
 
To test whether MCT1 and MCT4 are capable of transporting BCKAs across the 
membranes of living cells, heterologous expression in Xenopus oocytes (Hardwick and Philpott, 
2015) was used as a rapid, accessible and easy to manipulate model system. To evaluate the 
function of individual protein components of BCKA transport, the respective cRNAs were 
injected into Xenopus oocytes, stimulated the oocytes with BCAAs and KG, and determined 
changes in intra- and extracellular BCKA levels. Since the concentrations of BCKAs were 
expected to be lower than in the tumor cells the quantification of BCKAs in cell lysates as well 
as in the supernatants from oocyte cultures by UPLC was performed using the DMB 
derivatization agent. Expression of BCAT1 alone led to a significant increase in the intracellular 
levels of all three BCKAs compared to native oocytes or oocytes that expressed rat MCT1, rat 
MCT4 or the sodium/bicarbonate cotransporter (NBCe1) which was included to control for non-
specific excretion of BCKAs. When BCAT1 was co-expressed with either MCT1 or MCT4, 
intracellular BCKA concentrations significantly dropped (Figure 9A), suggesting that the MCTs 
mediated the excretion of the BCKAs produced by BCAT1.  
To further support this hypothesis, BCKA levels in the supernatants of the very same 
batches of oocytes (Figure 9B) were analyzed. Expression of the NBCe1 control did not affect 
BCKAs levels. Much larger increases of extracellular BCKA levels, however, were observed 
upon co-expression of human BCAT1 and either rat MCT1 or rat MCT4. BCKA concentrations 
in the supernatants reached about 25µM within 2 hours indicating that MCT1 and MCT4 can 
efficiently transport BCKAs across the membranes of living cells. 
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(Figure legend on the next page) 
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Figure 9 – Co-expression of BCAT1 and either MCT1 or MCT4 facilitates the excretion of BCKAs from 
Xenopus oocytes.  
BCKAs (KIV, KIC, KMV) levels detected by Ultra Performance Liquid Chromatography (UPLC) coupled to 
fluorescence detection in native oocytes or oocytes expressing BCAT1, MCT1, MCT4, NBCe1 or co-expressing 
MCT1 or MCT4 and BCAT1 stimulated with BCAAs (1 nmol L-Valin, 1 nmol L-Leucin, 1 nmol L-Isoleucin) and α-
ketoglutarate (3 nmol) for 2 h at RT (A) and in the oocytes culture medium (B). Heterologous expression of the 
human or rat proteins in the oocytes was performed by injection of the respective cRNA into the oocyte. The cRNA 
concentrations used were: 5 ng rat MCT1, 5 ng rat MCT4, 12 ng human BCAT1, 7 ng human NBCe1 or 5 ng MCT1 
or MCT4 and 12 ng BCAT1. Batches of 10 oocytes were used per condition. Values are mean ± SD of three 
biological replicates. Data generated with support of Prof. Holger M. Becker, TU Kaiserslautern, Kaiserslautern 
Germany. KIV: α-ketoisovalerate. KIC: α-ketoisocaproate. KMV: α-keto-β-methylvalerate. NBCe1: 
sodium/bicarbonate cotransporter. unpaired t-test * p<0.05; ** p<0.01; *** p<0.001 
3.1.4. Inhibition of MCT1 but not MCT4 reduces BCKA excretion from glioblastoma cells 
 
To investigate the role of MCTs in the transport of BCKAs in glioblastoma cells, we 
manipulated MCT function in the U87-MG, U251-MG and LN-229 cell lines by pharmacologic 
inhibition of MCT1 with the MCT1/MCT2-specific inhibitor AR-C155858 at concentrations that 
did not affect cell proliferation (Figure 10). 
 
 
Figure 10 – MCT1 inhibition does not impact on cell proliferation. 
Effect of MCT1 inhibitor AR-C155858 on cell proliferation of U87nt and U87shBCAT1 (A) and of U251nt and 
U251shBCAT1 (B) cells determined using the Click-iT proliferation assay. Values are mean ± SD for n = 2-3 technical 
replicates. unpaired t-test; ns: not significant 
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Application of AR-C155858 reduced the excretion of individual BCKAs 20% and 80% in 
U87-MG and LN-229, respectively (Figure 11A and B) while intracellular BCKA concentrations 
showed concurrent increases (Figure 11D and E). For unknown reasons, the effects of inhibition 
were less clear in U251-MG cells where in most cases we could only observe trends for 
decreases of excreted and increases of intracellular BCKAs, respectively (Figure 11C and F).  
Furthermore, consistently with the MCT1 inhibitor data, siRNA mediated knockdown of MCT1 
resulted in decreased excretion of BCKAs in the three glioblastoma cell lines (Figure 12). 
Inhibition of MCT1 also significantly decreased the excretion of pyruvate in all three cell lines 
(Figure 13A). This suggests that U251-MG potentially can compensate suppression of MCT1-
mediated transport of BCKAs but not pyruvate through another carrier system. Together these 
data indicate that MCT1 is an important mediator of the excretion of BCKAs as well as pyruvate 
by glioblastoma cells.  
To examine the role of MCT4 in BCKA transport in glioblastoma cells, siRNA-mediated 
knockdown was used since no specific inhibitors of MCT4 are commercially available. Despite 
good knockdown efficiencies in U87-MG and U251-MG cells using two different siRNA pools 
(Figure 14A), no significant changes in the levels of BCKAs in the cell culture media were 
observed (Figure 14B and C). To exclude the possibility that MCT4-mediated transport activity 
lost due to the siRNA knockdown was compensated by increased activity of MCT1, MCT4 
knockdown was performed with and without concurrent MCT1 inhibition in U87-MG cells. The 
combined inhibition of both MCTs did not result in any additive effect on BCKA excretion beyond 
that caused by MCT1 inhibition alone except for KIC (Figure 15).  
Furthermore, knockdown of MCT4 also did not reduce pyruvate excretion (Figure 13B 
and C). Together the data suggest that MCT4 has very limited transport capacities for BCKAs 
and pyruvate in glioblastoma cells. 
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Figure 11 – Inhibition of MCT1 transporter decreases BCKAs excretion in glioblastoma cells.  
BCKAs (KIV, KIC, KMV) levels were determined by Ultra Performance Liquid Chromatography (UPLC) coupled to 
fluorescence detection in supernatants from U87nt (A) , LN-229 (B) and U251nt (C) cells as well as in cell extracts 
(D, E, F) treated with  AR-C155858 for 24h at 37°C 10%CO2. BCKAs levels were normalized to total protein content 
and to the detected levels in the respective cells treated with DMSO (Control). (A, B, C, E) Values are mean ± SD of 
three independent experiments, run in triplicates. (D, F) Values are mean ± SD of two independent experiments, run 
in triplicates. Data generated with support of Dr. Gernot Poschet, COS, University of Heidelberg, Heidelberg, 
Germany. KIV: α-ketoisovalerate. KIC: α-ketoisocaproate. KMV: α-keto-β-methylvalerate. unpaired t-test; ns: not 
significant  * p<0.05 ** p<0.01 *** p<0.001  
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Figure 12 – MCT1 knockdown reduces BCKAs excretion. 
(A) Western blot analysis of MCT1 levels in U87-MG cells, U251-MG expressing normal levels of BCAT1 (U87nt and 
U251nt) and LN-229 cells 48h post transfection using of MCT1 siRNA (Dharmacon) or non-target siRNA (sint) 
(Dharmacon).  Anti-MCT1 (AB3538P, Millipore) antibody was used at 1:500 dilution. α-tubulin was used as loading 
control. BCKAs (KIV, KIC, KMV) levels were determined by Ultra Performance Liquid Chromatography (UPLC) 
coupled to fluorescence detection in supernatants from U87nt (B), U251nt (C) and LN-229 (D) cells 48h after 
transfection. BCKAs levels were normalized to total protein content and to the levels detected in U87nt, U251nt or 
LN-229 cells transfected with non-target (nt) siRNA (U87nt sint, U251nt sint or LN-229 sint, respectively). Levels are 
mean ± SD for n = 3 technical replicates. Data generated with support of Dr. Gernot Poschet, COS, University of 
Heidelberg, Heidelberg, Germany. KIV: α-ketoisovalerate. KIC: α-ketoisocaproate. KMV: α-keto-β-methylvalerate. 
unpaired t-test; ns: not significant  * p<0.05 ** p<0.01 **** p<0.0001  
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Figure 13 – MCT1 inhibition reduces pyruvate excretion.  
Pyruvate levels were determined by UPLC in supernatants from U87nt, U251nt and LN-229 cells treated with AR-
C155858 for 24h at 37°C 10%CO2 (A) and from U87nt (B) or U251nt (C) cells expressing normal MCT4 levels 
(sint) or low MCT4 levels (siMCT4). Pyruvate levels were normalized to total protein content and to the detected 
levels in the respective cells treated with DMSO (Control) or to the detected levels in cells expressing normal 
MCT4 levels (sint), respectively. (A) Values are mean ± SD for n = 3 technical replicates. (B, C) Values are mean 
± SD of two biological replicates. unpaired t-test; **** p< 0.0001. Data generated with support of Dr. Gernot 
Poschet, COS, University of Heidelberg, Heidelberg, Germany. 
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Figure 14 – MCT4 knockdown does not impact on BCKAs excretion.  
(A) Western blot analysis of MCT4 levels in U87-MG cells and U251-MG expressing normal levels of BCAT1 (U87nt 
and U251nt) 48h post transfection using MCT4 siRNA (Santa Cruz) (siMCT4 1), MCT4 siRNA (Dharmacon) (siMCT4 
2), or non-target siRNA (sint) (Dharmacon). Anti-MCT4 sc 50329 (Santa Cruz) antibody was used at 1:1000 dilution. 
α-tubulin was used as loading control. BCKAs (KIV, KIC, KMV) levels were determined by Ultra Performance Liquid 
Chromatography (UPLC) coupled to fluorescence detection in supernatants from U87nt (B) and U251nt (C) cells 48h 
after transfection. BCKAs levels were normalized to total protein content and to the levels detected in U87nt or 
U251nt cells transfected with non-target siRNA (U87nt sint or U251nt sint, respectively). Levels are mean ± SD of two 
biological replicates. Data generated with support of Dr. Gernot Poschet, COS, University of Heidelberg, Heidelberg, 
Germany. KIV: α-ketoisovalerate. KIC: α-ketoisocaproate. KMV: α-keto-β-methylvalerate 
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Figure 15 – MCT4 knockdown does not potentiate the effect of MCT1 inhibition on BCKAs excretion. 
BCKAs (KIV, KIC, KMV) levels were determined by Ultra Performance Liquid Chromatography (UPLC) coupled to 
fluorescence detection in supernatants from U87 cells expressing normal MCT4 levels (sint) or low MCT4 levels 
(siMCT4) treated with AR-C155858 for 24h at 37°C 10%CO2. BCKAs levels were normalized to total protein content 
and to the detected levels in cells expressing normal MCT4 levels (sint) treated with the MCT1 inhibitor. Values are 
mean ± SD for n = 3 technical replicates. unpaired t-test; ns: not significant; * p<0.05. Data generated with support of 
Dr. Gernot Poschet, COS, University of Heidelberg, Heidelberg, Germany. KIV: α-ketoisovalerate. KIC: α-
ketoisocaproate. KMV: α-keto-β-methylvalerate  
 
 
 
3.1.5. BCAT1 and MCTs are in close proximity in glioblastoma cells 
 
It has previously been shown that lactate-transport activities of MCT1 and MCT4 are 
enhanced by their close association with carbonic anhydrases, which serve as proton donors or 
acceptors to help drive co-transport of protons and lactate (Jamali et al., 2015; Klier et al., 
2014). Here we performed in situ proximity ligation assays (PLA) of MCT1, MCT4 and BCAT1 in 
U87-MG and U251-MG cells to test whether BCAT1, the enzyme producing the BCKAs in the 
cytoplasm, is located in close proximity to MCT1 and MCT4. We hypothesize that such an 
association might help increase local BCKA concentrations and enhance cross-membrane 
transport. In both cell lines we observed specific PLA signals indicating that BCAT1 and MCT1 
indeed are located in close proximity to one another (Figure 16A and B). Close proximity of 
BCAT1 and MCT4 also was detected in U251-MG cells (Figure 16D) but not in U87-MG cells 
(Figure 16C). To control for non-specific association of proteins, we performed PLA with the 
MCTs and the cytoplasmic metabolic enzyme phosphoglycerate kinase 1 (PGK1) in place of 
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BCAT1 (Figure 17B). PGK1 was selected because its level of protein expression is comparable 
to that of BCAT1 protein in U251-MG cells (NCI60 proteome resource: 
http://129.187.44.58:7070/NCI60/).  
Counting of the PLA signals revealed that the number of PLA signals/cell detected in the 
combination of anti-BCAT1 and anti-MCT1 antibodies was significantly higher than for the 
control combination of anti-PGK1 and anti-MCT1 antibodies in both cell lines (Figure 16E and 
F), suggesting specific close proximity between BCAT1 and MCT1 in glioblastoma cells.  
 
 
 
 
 
60 
 
 
 
Figure 16 – BCAT1 and MCTs are in close proximity in glioblastoma cells.  
Representative images of in situ proximity ligation assay (PLA) in the U87-MG (A, C) and U251-MG (B, D) cells 
expressing normal BCAT1 levels (U87nt, U251nt respectively) are shown. Cells were incubated with antibodies 
against BCAT1 and MCT1 or MCT4.  Cells incubated PGK1 and MCT1 or MCT4 antibodies were used as control 
and representative pictures are shown in Figure 17B. Magnification: 200x. Red, PLA signal; blue, DAPI. 
Quantification of PLA signals per cell in U87nt (E) and U251nt cells (F).   
Mann Whitney test; ns: not significant ; **** p< 0.0001.   
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Figure 17 – In situ proximity ligation assay controls.  
(A) Representative images of the negative controls of in situ proximity ligation assay (PLA) in U87nt cells. (B) 
Representative images of in situ PLA in the U87nt and U251nt cells. Cells were incubated with antibodies against 
PGK1 and MCT1 or MCT4. 
Magnification: 200x. Red, PLA signal; blue, DAPI. 
A 
B 
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3.1.6. BCKAs are taken up and metabolized by macrophages 
 
After characterizing the transport of BCKAs from glioblastoma cells I wanted to know 
whether the predominant cells of the glioblastoma stroma, i.e. tumor-associated macrophages, 
take up and catabolize tumor-secreted BCKAs, as recently had been shown for tumor-derived 
lactate. For this purpose, I first cultured human monocyte-derived, M-CSF-differentiated 
macrophages in the absence or presence of BCKAs (100 μM or 300 μM) and quantified BCKA 
levels in the culture media after 48 hours of culture using Ultra Performance Liquid 
Chromatography (UPLC). I observed that the BCKAs levels present in the culture medium of the 
M-CSF differentiated macrophages were not significantly changed compared to the levels 
detected in the medium without macrophages suggesting that the macrophages did not take up 
any BCKAs (Figure 18A). Second, I differentiated monocytes isolated from normal donors with 
U87nt and U87shBCAT1 conditioned medium (TCM) in the presence of human serum and 
treated them for the same 48 hours with 100 μM or 300 μM of BCKAs. These macrophages did 
not appear to take up the BCKAs present in the culture media (Figure 18B and C) similarly to 
what was observed for the M-CSF differentiated macrophages.  
To test whether small amounts of tumor-derived BCKAs still might be taken up and 
catabolized by macrophages, tracing experiments with non-radioactively labeled BCKAs in 
human monocyte-derived macrophages that had been differentiated with either M-CSF or 
tumor-conditioned media (TCM) were performed. After adding 13C-αKIC (1,2-13C2) and 13C-
αKIV (13C5) to the cell culture media for 48 hours, cell extracts were prepared from the 
macrophages and selected TCA cycle metabolites and amino acids (Table 2) analyzed by 
sequential gas chromatography and mass spectrometry (GC-MS). No detectable labeling in any 
of the analyzed metabolites was found when 100 μM of 13C-αKIC and 13C-αKIV were added to 
TCM differentiated macrophages (Table 2). However, regarding M-CSF differentiated 
macrophages cultured in the presence of 100 μM or 300 μM of 13C-αKIC and 13C-αKIV a more 
extensive analysis revealed M2 leucine labeling and M5 valine labeling, with increased labeling 
with increasing 13C-BCKA concentration (Figure 19C and D). Additionally, the analysis of the 
supernatants from the very same macrophage cultures by GC-MS revealed a decrease in M2 
KIC labeling (Figure 19A) and M5 KIV labeling (Figure 19B), comparing to the levels detected in 
the medium without macrophages. Together, these observations suggest that macrophages do 
take up BCKAs, contrasting with the data acquired using UPLC, and convert them into BCAAs. 
Additionally, the presence of unlabeled (M0) KIC or KIV in the supernatant from macrophage 
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cultures (Figure 19A and B) indicate that macrophages also synthesize and release BCKAs into 
the medium. The apparent discrepancy regarding the uptake of BCKAs by macrophages using 
the two distinct approaches mentioned above is further discussed in the discussion section of 
this thesis.    
 
 
 
  
64 
 
 
Figure 18 – Extracellular BCKA levels in BCKA-treated monocyte-derived macrophages. 
BCKAs (KIV, KIC, KMV) levels were determined by Ultra Performance Liquid Chromatography (UPLC) in 
supernatants from M-CSF differentiated macrophages cultured with 100 μM or 300 μM of BCKAs (A) or from 
macrophages differentiated using U87nt (nt: non-target) or U87shBCAT1 conditioned medium cultured with 100 μM 
(B) or 300 μM (C) of BCKAs and compared to the levels detected in the culture medium (DMEM) in the absence of 
macrophages. Data generated with support of Dr. Gernot Poschet, COS, University of Heidelberg, Heidelberg, 
Germany. Values are mean ± SD of two independent experiments, run in triplicates. KIV: α-ketoisovalerate. KIC: α-
ketoisocaproate. KMV: α-keto-β-methylvalerate. unpaired t-test; ns: not significant 
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Table 2 – List of intracellular metabolites analyzed by GC-MS after incubation of monocyte-derived 
macrophages with 100 μM or 300 μM of 
13
C-αKIC and 
13
C-αKIV for 48 hours.  
Monocytes were isolated from two different donors and differentiated into macrophages using either U87nt /shBCAT1 
tumor conditioned medium (TCM) or M-CSF. αKIC: α-ketoisocaproate. αKIV: α-ketoisovalerate. 
Macrophages [
13
C-αKIC + 
13
C-αKIV] (μM) Metabolite 
U8tnt TCM/U87shBCAT1 TCM 100 
Pyruvate 
Methionine 
Succinate 
Glutamine 
a-Ketoglutarate 
Alanine 
Aspartate 
Citrate 
Serine 
Lactate 
N-acetyl Aspartate 
Glycine 
Malate 
Glutamate 
Fumarate 
M-CSF 100/300 
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(Figure legend on the next page) 
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Figure 19 - BCKAs are taken up by human-monocyte derived macrophages and converted to BCAAs.  
(A, B) KIC (A) and KIV (B) labeling pattern was determined by sequential gas chromatography and mass 
spectrometry (GC-MS) in supernatants from M-CSF differentiated macrophages cultured with 100 μM (1) or 300 μM 
(3) of 
13
C-αKIC and 
13
C-αKIV and compared to the levels detected in the medium (ctrl) with 100 μM (100) or 300 μM 
(300) of BCKAs in the absence of macrophages. 
Leucine (C) and Valine (D) labeling pattern was determined by GC-MS in cell extracts from M-CSF differentiated 
macrophages cultured with 100 μM (1) or 300 μM (3) of 
13
C-αKIC and 
13
C-αKIV. Values are mean ± standard error of 
the mean of n=3 technical replicates. Monocytes were isolated from two different donors (D1, D2). Y-axis: Relative 
abundance of each mass isotopomer (M). M0, M1 to Mn: M is the base mass of an ion fragment and the following 
number from 0 to n (active carbon number) indicates the mass shift from M. Data generated with support of Yannic 
Nonnenmacher, TU-BS, Braunschweig, Germany. 
 
3.1.7. BCKAs reduce macrophage phagocytosis 
 
Glioblastoma exert strong immuno-suppressive effects on their microenvironment 
including the suppression of macrophage phagocytic activities (Hambardzumyan et al., 2016). It 
is unclear what role tumor-derived metabolites might have in this process. Here, I considered 
whether BCKAs could directly affect the phagocytic properties of macrophages. For this 
purpose the engulfment of fluorescent beads by monocyte-derived macrophages was assessed. 
Once the beads were biotin-labeled we first discriminated between engulfed and non-engulfed 
beads using streptavidin PE (Figure 20A). Considering only engulfed beads, we observed a 
significant decrease in the number of beads in the macrophages cultured with 300 μM of BCKAs 
compared to the cultures not exposed to BCKAs (Figure 20C), suggesting that tumor cell-
derived BCKAs can affect the tumor microenvironment in glioblastoma by suppressing 
phagocytosis by tumor-associated macrophages. 
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Figure 20 – BCKAs reduce macrophage phagocytosis in vitro. 
(A) Streptavidin PE (red) binds to non-engulfed biotin-labeled fluorescent beads (green) resulting in an orange 
staining under fluorescence microscope. (B) Comparison between the number of fluorescent beads (green) engulfed 
by macrophages cultured with and without BCKAs was assessed using fluorescence microscopy. Plasma membrane 
(red) is stained with Cell Mask stain. (A), (B) Hoechst stains nuclei (blue). Scale bar: 40μm. (C) The number of beads 
engulfed by each cell was quantified using ImageJ software. Line represents mean (monocytes were isolated from 
two different donors and 3-4 fields per condition were examined). Mann Whitney test; ** p<0.01   
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Aiming to explain the observed effect on macrophage phagocytosis caused by BCKAs 
gene expression arrays of monocyte-derived macrophages differentiated in the presence or 
absence of BCKAs were performed. It was observed that BCKA treatment had a minor impact 
on macrophages’ expression profiles. This is evident from the observed low fold-change 
differential expression (2.34 max.) (Supplementary table 2) (Appendix) as well as minor 
deviations from the diagonal evident in the X/Y-plot of BCKA-treated and control samples 
(Figure 21A). However, analysis of the data using gene set enrichment analysis (GSEA) 
revealed a significant (nominal p-value<0.01 and FDR<0.25) enrichment for genes involved in 
hypoxia and angiogenesis and also, less significant (nominal p-value<0.05 and FDR>0.25), in 
epithelial-mesenchymal-transition and glycolysis (Figure 21B-E) in macrophages treated with 
300μM BCKAs in comparison to untreated (control) macrophages.  
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Figure 21 – Differential expression analysis (A) and Gene Set Enrichment Analysis (GSEA) (B-E) of 
macrophages treated with 300 μM BCKAs in comparison to untreated (control) macrophages. 
(A) Scatterplot profiles of differential gene expression in macrophages treated with 300μM BCKA versus untreated 
macrophages. Axes represent the mean (n=4) expression values in log2 scale. Diagonal line represent an expression 
ratio of 1 (similar levels of expression in BCKA-treated and untreated macrophages). Monocytes were isolated from 
four different donors. Data generated jointly with Dr. Ann-Christin Gaupel, Department of Molecular Genetics, 
German Cancer Research Center (DKFZ), Heidelberg, Germany. ES: enrichment score; NES: normalized enrichment 
score; FDR: false discovery rate  
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3.2. Manipulation of BCAT1 expression in the tumor compartment affects 
stromal cell phenotype 
 
After studying the impact of BCKAs in the stromal cell phenotype I aimed to investigate 
the effects of BCAT1 knockdown in the tumor cells on the stromal cell phenotype.  
3.2.1. shBCAT1 TCM promotes survival and differentiation of monocytes  
 
The effect of manipulation of BCAT1 in the tumor compartment on the cells of the stroma 
compartment was assessed next. To accomplish this aim, we differentiated monocytes in the 
presence of conditioned medium harvested from U87 cells expressing low or normal levels of 
BCAT1 (2.2.12.2). In a first instance monocytes isolated from buffy coats were used and the 
results were also validated using the U937 monocytic cell line model. It was observed that 
U87shBCAT1 TCM promoted survival and differentiation of monocytes (Figure 22).  
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Figure 22 – BCAT1 knockdown TCM promotes monocyte survival and differentiation to macrophages. 
(A) Representative pictures of monocytes differentiated in the presence of U87nt (nt: non-target) or shBCAT1 TCM in 
comparison to those differentiated in the presence of human M-CSF. Magnification: 200x. (B) U937 cells were 
differentiated to macrophages using 5 nM PMA in DMEM medium or in the presence of U87nt or shBCAT1 TCM for 
48h. Counts of viable cells/mL were obtained using a Vi-cell counter. (A) Experiment was performed twice. (B) 
Experiment was performed once. 
3.3.2 BCAT1 knockdown modulates monocyte-derived macrophage expression profile 
 
Gene set enrichment analysis (GSEA) indicated a significant (nominal p-value<0.01 and 
FDR<0.25) positive enrichment of interferon (IFN) alpha and gamma responses in 
macrophages differentiated with shBCAT1 TCM (shBCAT1-M) compared to non-target (nt) TCM 
(nt-M) (Figure 23). This suggests that the expression of BCAT1 in the glioblastoma cells might 
suppress macrophage inflammatory response. Among the deregulated genes present in the 
interferon gamma response pathway, a downregulation of the IFN-induced ubiquitin-like protein 
(UBL) ISG15 – described by others as a regulator of macrophage activation and phagocytosis 
(Yanguez et al., 2013), was observed in TAMs exposed to nt TCM vs shBCAT1 TCM 
(Supplementary figure 1) (Appendix). We hypothesize that the high BCKAs levels present in the 
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nt TCM can decrease ISG15 expression, contributing to the observed decrease in macrophage 
phagocytosis.  
 
 
 
Figure 23 – Macrophages differentiated with U87 shBCAT1 medium or U87nt medium display different 
expression profiles. 
GSEA enrichment plots for the Hallmark_Interferon_alpha_response (A) and Hallmark_Interferon_gamma_response 
(B) for macrophages differentiated with U87shBCAT1 medium (shBCAT1–M, n = 4) comparing to U87nt differentiated 
ones (nt–M, n = 4). ES: enrichment score; NES: normalized enrichment score; FDR: false discovery rate 
 
 
To investigate the effect of BCAT1 knockdown in the tumor cells a gene expression 
array for U87 cells expressing normal (nt) or low BCAT1 levels (shBCAT1) was performed. 
Differential expression analysis of the data and the investigation of the top 60 deregulated 
genes revealed upregulation of CCL2 after BCAT1 knockdown (Supplementary table 3).  
Next the effect of BCAT1 knockdown in the production of tumor-derived factors, 
specifically cytokines was investigated. An increase in the levels of MCP-1/CCL2 was observed, 
which is in accordance with the observed increased in gene expression, and slight increases in 
GRO, IL-6 and IL-8 after BCAT1 knockdown (Figure 24). The remaining cytokines present in the 
array (Appendix) were not affected by BCAT1 knockdown. 
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Figure 24 – Overview of the cytokine panel for the 80 cytokines including the internal assay controls and 
representative blots.  
Positive (POS) and negative (NEG) controls are shown. Highlighted are the cytokines that were upregulated or 
downregulated in U87shBCAT1 TCM with solid or dashed line, respectively, comparing to U87nt TCM. 
 
3.3.3 Monocyte migration is not affected by BCAT1 knockdown in the tumor cells  
 
The effect of BCAT1 knockdown in the tumor cells on the migratory potential of 
monocytes was assessed using transwell migration assay. Application of U87shBCAT1 TCM 
(2.2.12.1) showed no evident chemotactic potential of monocytes comparing to U87nt TCM 
(Figure 25). When comparing the number of migrated cells to the tumor conditioned medium 
with the CCL2 it was observed that the conditioned medium has higher chemotactic potential of 
monocytes suggesting the involvement of other tumor-derived factors in addition to CCL2.  
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Figure 25 – Monocyte migration assay.  
Transwell migration assay with monocytes seeded in upper chamber, 2h migration prior to harvest and cell counting. 
Indicated chemoattractants were applied in lower chamber: U87nt (nt: non-target) TCM, U87shBCAT1 TCM, DMEM, 
CCL2. Monocytes were isolated from three independent donors. Values are mean ± SD. Data generated jointly with 
Dr. Ann-Christin Gaupel, Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, 
Germany. 
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4. Discussion 
 
In the current study, a comprehensive characterization of the branched-chain ketoacids 
transport in living cells was performed. In a first instance, the production and excretion of these 
metabolites was characterized in two distinct systems (tumor cell lines and Xenopus oocytes). 
MCT1 and MCT4 were identified as potential BCKAs transporters in living cells with MCT1 
being involved in the excretion of BCKAs from glioblastoma cell lines. In a second instance, I 
evaluated the role of the BCKAs in the tumor-stroma interaction using macrophages as a model 
of the stromal compartment. In this model, BCKAs were taken up and catabolized by 
macrophages and impaired macrophage phagocytosis. Finally, I generated data characterizing 
the stromal cell phenotype after modulating BCAT1 expression in the tumor cell compartment. 
 
4.1 MCT1-mediated excretion of glioblastoma cell branched-chain 
ketoacids modulates macrophage phagocytosis 2  
 
Glioblastoma cells excrete BCKAs 
 
Glioblastoma are characterized by overexpression of the metabolic enzyme BCAT1 and 
associated excretion of glutamate, features that are well-conserved in cell line models (Tönjes 
et al., 2013). In glioma patients glutamate excretion was shown to cause tumor-associated 
epilepsy (Buckingham et al., 2011). In the present work I could show that BCKAs, which are 
generated by BCAT1 alongside glutamate, also are excreted by glioblastoma cells, resulting in 
the accumulation of high concentrations (in the μM range) in the culture media within 24 hours. 
The observation that tumor cells excrete BCKAs was intriguing since these metabolites have 
been reported to be important energy sources (Kainulainen et al., 2013). However, others have 
shown that BCKAs can be excreted from cells, i.e. during overnight fasting when BCAAs are 
transaminated to BCKAs in muscle cells which get excreted and transported to the liver for 
further oxidation (Hutson et al., 2005). In support of the idea that tumor cells might excrete 
                                               
2
 This chapter is the subject of a manuscript entitled “MCT1-mediated excretion of glioblastoma cell branched-chain ketoacids 
modulates macrophage phagocytosis” which is currently submitted at EMBO Reports, and of which I am the first author and has 
been originally written by myself.  
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BCKAs for their own benefit are the observations that accumulation of toxic levels of BCAAs 
and BCKAs in tissues in maple syrup urine disease (MSUD), a heritable defect of BCAA 
catabolism, has been shown to affect cell energy metabolism and cell survival (Amaral et al., 
2010; Hutson et al., 2005; Sgaravatti et al., 2003).    
MCTs mediate BCKAs excretion  
 
It has been previously described that MCTs have affinity for the transport of α-ketoacids 
(Manning Fox et al., 2000) and that the transport of α-ketoisocaproate (KIC), the ketoacid of 
leucine, in neurons involves one of the MCT proteins (Mac et al., 2000). The query of published 
data of primary untreated glioblastoma (n=480; TCGA dataset) revealed that both MCT1 and 
MCT4, but not MCT2 or MCT3, were significantly overexpressed compared to normal brain lead 
us to select these two members of the MCT family as potential BCKAs transporters. MCT1 and 
MCT4 overexpression in glioblastoma was corroborated by others (Lim et al., 2014; Miranda-
Goncalves et al., 2013; Takada et al., 2016). Using Xenopus oocytes as a heterologous 
expression system showed that MCT1 and MCT4 can mediate the transport of all three BCKAs 
across the membranes of living cells. These data are consistent with and extend previous 
studies showing that uptake of KIC and KIV can be mediated by MCTs in Xenopus oocytes 
(Bröer et al., 1998; Halestrap, 2012).  
 
Modulation of MCT1 and MCT4 transport capacity  
 
Suppression of MCT1 by the MCT1/2-specific inhibitor AR-C155858 (Nancolas et al., 
2015) in glioblastoma cell lines indicated that BCKAs are excreted from the tumor cells via 
MCT1. Since AR-C155858 also inhibits MCT2 when it is associated with the ancillary protein 
CD147 (Nancolas et al., 2015) one cannot exclude a role of MCT2 in BCKAs export in vitro. 
However, major effects on BCKAs export appear unlikely given that MCT2 rarely associates 
with CD147 in mammalian cells (Ovens et al., 2010) and furthermore is downregulated in tumor 
compared to normal brain. Inhibition of MCT1 also significantly reduced the efflux of pyruvate in 
all three glioblastomas cell lines consistent with similar observations reported for mammary 
carcinoma cell lines (Hong et al., 2016). Knockdown of MCT4 did not appear to affect the efflux 
of BCKAs or pyruvate in my analysis. These observations indicate that while both MCT1 and 
MCT4 are in principle capable of transporting BCKAs, MCT4-mediated transport appears to be 
attenuated in glioblastoma cells. In part this might be explained by differences in substrate-
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dependent transport kinetics. Estimates of Michaelis-Menten constants for MCT1 and MCT4 
mediated transport in Xenopus oocytes (summarized in (Halestrap, 2012)) are suggesting 
preferred transport of KIC, KIV and pyruvate by MCT1 (KIC, KIV and pyruvate ~ 1mM vs. 
lactate 3.5mM) and of lactate by MCT4 (lactate 28mM vs. KIC, KIV and pyruvate ~100-150mM). 
This is consistent with the idea that in cells that express both MCT1 and MCT4, BCKAs and 
pyruvate, which are present in the cell at lower concentrations, will preferentially be transported 
by the high-affinity carrier MCT1, while lactate, which is produced in vast amounts in cancer 
cells, will be excreted via the high-capacity transporter MCT4. 
Despite the lack of evidence for the involvement of MCT4 in BCKA transport in 
glioblastoma, the observation that MCT4 is significantly upregulated in the mesenchymal 
subtype of glioblastoma is still relevant in the context of glioblastoma. This observation agrees 
with what others have published (Lim et al., 2014) and suggests MCT4 as a subtype specific 
gene in glioblastoma. MCT4 has also been identified as a subtype specific gene in other tumor 
entities, namely in pancreatic cancer, where MCT4 defines a glycolytic subtype of these tumors 
(Baek et al., 2014). In glycolytic tumors, cells produce large amounts of lactate and upregulation 
of MCT4 allows them to eliminate excess lactate and survive (Baek et al., 2014). These 
observations support our assumption that MCT4 will preferentially excrete lactate.  
Transport of metabolites might be further regulated through spatial association of 
proteins resulting in locally increased metabolite concentrations. In this work, data from in situ 
PLA indicate that BCAT1 and MCTs are in close proximity in glioblastoma cells. Hypothetically, 
this might serve to further optimize BCKA transport by increasing local BCKA concentrations in 
the vicinity of the MCTs. Previous studies have provided evidence for an analogous mechanism 
that the proximity of Carbonic Anhydrase II (CAII) to MCT1 and MCT4 supports the 
proton/lactate co-transport with CAII acting as a “H+-collecting antenna” and increasing the 
concentration of protons in the vicinity of MCTs (Becker et al., 2011; Noor et al., 2015; Stridh et 
al., 2012). 
 
A similar pattern of metabolite transport as observed in this study was recently reported 
for mammary carcinoma (Hong et al., 2016). In triple negative breast cancer (TNBC) cell lines, 
the authors found a segregation of metabolite excretion, with pyruvate and lactate export being 
exclusively mediated by MCT1 and MCT4, respectively. Further, suppression of MCT1-
mediated transport switched tumor metabolism to a more oxidative state and blocked mammary 
carcinoma growth in vitro and in a xenograft model  (Hong et al., 2016). A query of published 
microarray data (GSE76675) of the three breast cancer cell lines (HS578T, SUM149 and 
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SUM159) used in this study revealed all as having high levels of BCAT1 expression. 
Interestingly, it has been shown that in TNBC, BCAT1 almost always is highly overexpressed 
and is essential for tumor growth in cell line and animal models (Thewes et al., 2017), 
suggesting that TNBC likely will secrete BCKAs in addition to lactate and pyruvate. This raises 
the interesting possibility that intracellular accumulation of BCKAs in addition to pyruvate might 
be causing the growth inhibition that was observed following MCT1 suppression in several 
studies (Hong et al., 2016; Takada et al., 2016). It will be difficult to address this question since 
transport of pyruvate and BCKAs via MCT1 might co-occur in many tumors. However, the 
effects of accumulation of BCKAs in MSUD patients on cell energy metabolism and cell survival 
(Amaral et al., 2010; Jouvet et al., 2000; Sgaravatti et al., 2003) suggest that blocked BCKA 
export might be responsible for at least part of the observed phenotype (growth inhibition). 
These results expand upon a growing literature on MCT1 involvement in the transport of 
tumor-derived metabolites and provide further evidence for the eminent role of BCAA 
catabolism in glioblastomas. Furthermore, the anti-proliferative effects of MCT1 knockdown 
observed by others (Hong et al., 2016; Takada et al., 2016) might be in part due to intracellular 
accumulation of BCKAs in addition to pyruvate, adding additional support for the concept of 
using MCT1 inhibitors as anti-cancer therapeutic drugs. 
BCKAs are taken up by macrophages and metabolized to BCAAs 
 
After characterizing the transport of BCKAs from glioblastoma cells I wanted to know 
whether the predominant cells of the glioblastoma stroma, i.e. tumor associated macrophages, 
take up and catabolize tumor-secreted BCKAs, as recently had been shown for tumor-derived 
lactate in mammary carcinoma (Nakajima and Van Houten, 2013). In this model, lactate is 
produced and excreted via MCT4 by CAFs and taken up by oxygenated tumor cells via MCT1 
for ATP production. An analogous exchange of metabolites, in this case the amino acids 
glutamate/glutamine and a BCAT cycle has been proposed to occur in the normal brain for 
nitrogen balance maintenance (Bak et al., 2013; Leke et al., 2011). In the present work, isotope 
tracing analysis provided evidence of a similar metabolite transfer, in which tumor-derived 
BCKAs appear to be taken up by macrophages and converted to BCAAs. Others have recently 
shown that in non-small cell lung cancer cells BCAAs can be directly incorporated into protein 
supporting the needs of rapidly proliferating cells (Mayers et al., 2016). However, the metabolic 
fate of BCAAs in macrophages, considered as non-proliferative cells in vitro, remains poorly 
described. 
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Intriguingly, the quantification of BCKAs in BCKA-treated macrophage supernatants 
using UPLC did not reveal significant reduction of BCKAs levels compared to those detected in 
the medium without macrophages, failing to support the isotope tracing data that suggest that 
macrophages take up labeled BCKAs. However, isotope tracing experiments also revealed the 
presence of high levels of unlabeled (M0) KIC and KIV in the 13C2-KIC- and 13C5-KIV-treated 
macrophage supernatants, respectively, suggesting that macrophages are able to produce and 
secrete BCKAs. Given that in the UPLC experiments total BCKAs levels present in the 
supernatant after 24 hours of BCKA treatment are detected, we hypothesize that the decrease 
in BCKAs levels is not observed due to the concurrent secretion of BCKAs by macrophages.           
 
BCKAs decrease macrophage phagocytosis 
 
The impact of BCKAs in the cells from the stromal compartment has not been studied so 
far. In the present study it was shown that macrophages cultured in the presence of 300μM of 
BCKAs display reduced phagocytic capacity in vitro. Reduced phagocytic activity has been 
associated with an immunosuppressive phenotype of infiltrating macrophages that can be 
induced by glioma (Hussain et al., 2006; Li and Graeber, 2012). At the expression level, BCKAs 
did not induce evident changes of the macrophage expression profile, hampering the 
identification of the mechanism by which these metabolites affect phagocytosis. Interestingly, in 
this study it was provided evidence for BCKA uptake by macrophages and their conversion to 
BCAAs. These observations raise the question whether the observed effect of BCKAs-treatment 
on macrophage phagocytosis is directly mediated by BCKAs or dependent on their catabolism 
to BCAAs. Nevertheless, the observation that exposure of monocytes to U87 or U251 
conditioned medium, which I showed here contains high levels of BCKAs, reduced their 
phagocytic ability (Rodrigues et al., 2010) is supporting the hypothesis that BCKAs are affecting 
phagocytosis by glioma-associated macrophages.   
Analysis of gene expression arrays of macrophage cultured in the presence or absence 
of BCKAs using gene set enrichment analysis (GSEA) revealed an enrichment of genes 
involved in glycolysis in BCKA-treated macrophages. Others have shown that TAMs generated 
in vitro exhibit a pronounced glycolytic signature in a metabolic flux assay, corresponding with 
elevated glycolytic gene transcript levels that correlated with pro-metastatic phenotype (Penny 
et al., 2016). However, the factors, present in the conditioned medium that could be responsible 
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for promoting the phenotype, were not identified (Penny et al., 2016). Here, the data suggest 
that BCKAs can be one of the tumor-derived factors with impact on macrophage phenotype.      
 
4.2 Manipulation of BCAT1 expression in the tumor compartment affects 
the stromal cell phenotype 
 
Here I showed that conditioned medium from U87 cells expressing low BCAT1 levels 
impacted stromal cell, specifically, monocyte and macrophage phenotype. However, the tumor-
derived factors involved in this process remain poorly understood, since alterations in BCKAs 
levels are only one among several consequences of BCAT1 knockdown. This is a very 
interesting topic but given the complexity of studying tumor-stroma interactions in vitro only 
preliminary data were generated. Gene set enrichment analysis of monocyte-derived 
macrophages differentiated in the presence of tumor conditioned medium indicated significant 
positive enrichment of interferon (IFN) alpha and gamma responses in macrophages 
differentiated with U87shBCAT1 TCM compared to U87nt TCM. The data suggest that BCAT1 
expression, associated with production and secretion of BCKAs and other factors by the tumor 
cells, suppresses macrophage inflammatory response supporting tumor progression. Others 
showed that IFN-gamma priming of macrophages repressed part of the inflammatory program 
and attenuated neutrophil recruitment to inflammatory sites (Hoeksema et al., 2015). Moreover, 
it was shown that normal human monocytes exposed to malignant glioma cells, expressing 
BCAT1, adopt an immunosuppressive phenotype characterized by reduced phagocytic/antigen 
presenting ability and increased ability to induce apoptosis in activated T cells (Rodrigues et al., 
2010). Among the deregulated genes present in the interferon gamma response pathway a 
downregulation of the IFN-induced ubiquitin-like protein (UBL) ISG15, described by others as a 
regulator of macrophage activation and phagocytosis (Yanguez et al., 2013), was observed in 
TAMs exposed to nt TCM vs shBCAT1 TCM. I hypothesize that the high BCKAs levels present 
in the nt TCM can decrease ISG15 expression, contributing to the observed decrease in 
macrophage phagocytosis. In agreement with these data, others have shown that ISG15-/- 
macrophages displayed reduced activation and phagocytic capacity comparing to the ISG15+/+ 
cells (Yanguez et al., 2013). However, using the BCAT1-knockdown conditioned medium, the 
effect of factors other than BCKAs in the observed modulation of macrophage phagocytosis 
cannot be excluded.  
In addition, I showed that conditioned medium from U87 cells expressing low BCAT1 
levels promoted survival and differentiation of monocytes. However, an important aspect that 
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has to be considered is that the generation of U87nt and shBCAT1 conditioned medium used in 
the assays where macrophages survival and differentiation was assessed, did not take into 
account the differences in cell proliferation caused by BCAT1 knockdown (Tönjes et al., 2013). 
Thus, an impact of different nutrient availability in the alterations observed in the survival and 
differentiation of monocytes cannot be excluded.  
Aiming to further characterize the impact of BCAT1 knockdown in the tumor cells on the 
stromal cell phenotype, the migration of monocytes towards tumor-cell conditioned medium was 
investigated. An increase in the expression of CCL2 at the RNA and protein level that was 
translated into higher secretion of CCL2 after BCAT1 knockdown in U87 cells was observed. 
CCL2 is a clinically relevant cytokine in glioblastoma supported by the observation that in 
clinical specimens of glioblastoma, elevated levels of CCL2 expression correlated with reduced 
overall survival of patients (Chang et al., 2016a). Moreover, given the previous reports 
suggesting an important role of CCL2 in mediating the dialog between glioma cells and 
microglia (Zhang et al., 2012) and its role as monocyte/macrophage chemoattractant (Bonapace 
et al., 2014; Pena et al., 2015), the chemoattractant properties of U87 BCAT1-knockdown 
conditioned medium in comparison to U87nt medium were evaluated. However, the application 
of BCAT1-knockdown medium in comparison to U87nt medium did not show any evident 
change of the chemotactic potential of monocytes. In mammary tumors, estrogen receptor (ER)-
α+ tumors that are characterized by low BCAT1 expression (Thewes et al., 2017) have reduced 
immune cell infiltration compared to ER- and progesterone receptor (PR)-negative subtypes 
(Sousa et al., 2015). Since the tumor conditioned medium displayed higher chemotactic 
potential of monocytes than CCL2, one can hypothesize that monocyte migration is in the 
scenario being affected by other factors present in the conditioned medium, and independently 
of BCAT1 knockdown. Others have recently shown that periostin is a glioma-secreted factor that 
promotes recruitment of monocytes and macrophages (Guo et al., 2016; Zhou et al., 2015).   
Moreover, the impact of tumor-derived CCL2 in the stromal cell compartment may 
involve cell types other than monocytes demonstrating the complexity of the tumor-stroma 
interaction. Others have recently shown that glioma microenvironment-derived CCL2 recruits 
regulatory T cells and myeloid-derived suppressor cells (Chang et al., 2016a). 
The study of metabolite exchange in the tumor-stroma interaction in vitro is demanding 
and has the limitation that it represents only a subtype of the stromal cell compartment at a time. 
Besides the effect of tumor-secreted BCKAs in the macrophage phenotype such as 
phagocytosis, in the complex tumor-stroma interaction it has been shown that promotion of 
phagocytosis can in turn impact on other cells from the stromal compartment. It has been 
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recently shown that butyrate, a microbial-derived metabolite, promoted phagocytosis in IL-4-
induced macrophages that can limit T-cell production of IL-17A revealing an important aspect of 
bacterial-host interaction in the regulation of intestinal homeostasis (Fernando et al., 2016).   
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5. Outlook 
 
In future studies the mechanism through which tumor-secreted BCKAs contribute to the 
observed decrease in macrophages phagocytosis needs to be clarified in detail to determine 
whether, as suggested by the data reported here, this phenotype is induced through signals that 
do not involve alterations in the gene expression of the macrophages.  
Regarding the role of tumor-secreted BCKAs in tumor progression it would be intriguing 
to quantify BCKAs secretion in triple negative breast cancer cell lines that also depend on high 
BCAT1 expression for sustained growth. This will help to evaluate the hypothesis that the anti-
proliferative effects of MCT1 knockdown observed by others might be related to the blocked 
excretion of BCKAs. 
Furthermore, it would be of great interest to extend the work on the effects of BCAT1 
knockdown in the tumor compartment on the stroma compartment to other cell types such as T 
cells, given that preliminary results (Supplementary figure 2) (Appendix) suggested that culture 
medium from U87 cells after BCAT1 knockdown stimulated CD8+ T cell proliferation in vitro. 
These data imply that BCAT1-knockdown conditioned media are less immunosuppressive than 
control media, adding additional support for the concept of using BCAT1 inhibitors as anti-
cancer therapeutics.  
As the modulation of the tumor-stroma interaction in vitro has proven to be very complex 
and the data obtained difficult to interpret, these studies could benefit from the establishment of 
in vivo models to further characterize the impact of metabolite exchange between tumor and 
stromal cell compartments and the consequences to tumor progression. 
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8. Appendix 
 
 
Supplementary table 1 – Metabolite levels detected by Ultra Performance Liquid Chromatography (UPLC) in cell 
extracts (pmol/million cells) using the DMB derivatization method and in cell culture supernatants and in commercial 
DMEM (μM) using the OPD derivatization method.  
KIV: α-ketoisovalerate. KIC: α-ketoisocaproate. KMV: α-keto-β-methylvalerate; n.d not detected 
 
 
DMB method OPD method 
Metabolite 
Levels (pmol/mio cells) - 
cell extracts 
Levels (μM) - cell culture 
supernatants 
Levels (μM) - DMEM  
KIV 3-16 20-40 n.d 
KIC 5-35 40-85 n.d 
KMV 7-28 40-85 n.d 
Pyruvate high background 30-130 2-3.5 
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Plasmid maps 
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Human Cytokine array maps 
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Supplementary table 2 – List of top20 fold changes after differential analysis of BCKA-treated macrophages 
in comparison to untreated (control) macrophages.  
Gene BCKAs mean Control mean BCKAs vs. control fold change 
IL8 2207.41 945.35 2.34 
PPBP 4151.8 2144.08 1.94 
TACSTD2 1095.33 570.95 1.92 
ADM 2820.33 1499.69 1.88 
IL8 610.98 348.23 1.75 
 596.14 352.29 1.69 
SLC39A8 509.17 837.15 0.61 
CXCL1 289.65 176.7 1.64 
MMP12 211.67 132.47 1.6 
P4HA1 792.79 504.84 1.57 
CXCL5 1235.6 792.93 1.56 
LGMN 2201.06 3361.13 0.65 
CLLU1OS 826.85 543.41 1.52 
DDIT4 732.43 483.95 1.51 
LGMN 1189.13 1792.21 0.66 
C1QC 1334 1996.87 0.67 
CKS2 640.58 944.8 0.68 
HSPA6 386.66 264.13 1.46 
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PLOD2 200.48 137.7 1.46 
SLC2A1 346.6 241.58 1.43 
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Supplementary figure 1 – Macrophages differentiated with U87 shBCAT1 medium or U87nt medium display 
different expression profiles.  
Expression heat map for the Hallmark_Interferon_gamma_response for macrophages differentiated with 
U87shBCAT1 medium (shBCAT1–M, n = 4) comparing to U87nt differentiated ones (nt–M, n = 4).  
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Supplementary table 3 – List of top60 fold changes after differential analysis of U87shBCAT1 cells in 
comparison to U87nt cells.  
Gene U87shBCAT1 mean U87nt mean U87shBCAT1 vs. U87nt fold change 
SCG2 2214.709045 93.7519299 23.62307685 
TMEM119 1867.096884 177.5250351 10.51737228 
STMN3 1268.235829 157.5570893 8.049373307 
TGFB3 2413.012782 406.9095429 5.930096317 
SIDT2 1684.941689 291.8235467 5.773837335 
CYBASC3 3619.178513 702.120406 5.154640831 
AKR1B10 1872.710438 365.0159129 5.130489855 
CRYGS 535.1100999 106.6719332 5.016409508 
HCP5 426.2150221 85.29204986 4.997124853 
COL5A2 1755.644119 354.3781855 4.954154039 
HSPB3 981.7110333 202.7276716 4.842511264 
FAIM2 972.5626291 202.2311702 4.809162841 
ADM 5127.621376 1068.379013 4.799440381 
CFI 853.8071751 179.8272414 4.747930115 
FLVCR2 1601.064901 355.8925179 4.498731557 
LEPREL1 1112.246014 254.0379938 4.378266406 
C21orf121 591.3750387 141.8482592 4.169068004 
CGNL1 452.6282723 111.6604066 4.053614759 
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HCFC1R1 1008.938194 255.5521201 3.948072095 
AQP9 2878.543802 742.8528873 3.874985009 
LRRC17 376.318448 99.01885862 3.800472489 
KIAA1199 1248.086765 329.3962752 3.789012988 
CCL2 303.9872724 82.89332119 3.667210676 
MFAP4 3306.271114 913.4494159 3.619544834 
RFTN2 388.2066049 107.6924908 3.60476949 
NR2F1 714.9705606 199.35044 3.58650104 
SAT1 2101.40227 596.7404039 3.521468056 
IGFBP3 641.1040215 183.4349582 3.49499369 
YPEL2 370.7232405 107.3666429 3.452871678 
MAFB 2054.280586 603.3873107 3.404580358 
BCAT1 141.3169487 1548.897745 0.091237107 
VIL2 273.0487683 1778.057293 0.153565787 
EZR 470.1618591 3002.889203 0.156569832 
AXL 428.2370133 2326.603799 0.184060996 
CEP55 262.8478785 1426.851578 0.184215291 
CNIH4 508.5440192 2343.739705 0.216979735 
PPM1F 254.2078691 1149.688747 0.221110166 
HSP90AB1 632.2350851 2811.79346 0.224851183 
CDC20 1150.506112 5000.668044 0.230070483 
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PRC1 439.1861322 1883.370878 0.233191528 
HNRNPD 1472.76046 6207.606031 0.237250955 
TOP2A 473.7013864 1996.562486 0.237258483 
GINS2 340.3335287 1412.161193 0.241001899 
FAM83D 183.4983346 749.9322767 0.244686541 
PBK 266.8714535 1062.323111 0.251214956 
PODXL 102.7769012 402.2733125 0.25549023 
UBE2C 599.0872027 2312.296924 0.259087488 
NSMAF 229.9038071 886.5380559 0.259327623 
CCNB2 460.265289 1761.01402 0.261363785 
TRIB3 187.2138635 714.1019904 0.262166842 
LSM14A 269.2634046 1011.462163 0.266212039 
CDCA5 331.971421 1230.618649 0.269759784 
MCM3 847.2450178 3126.139472 0.271019584 
CDCA7 191.2168573 699.9084426 0.273202673 
DLGAP5 339.0962419 1234.001528 0.274794021 
FJX1 358.0659257 1298.194984 0.275818294 
TRIP13 320.4616059 1156.371166 0.277126943 
MELK 328.2925602 1181.273456 0.277914109 
AURKB 197.7867771 704.897095 0.280589576 
CDCA4 160.1998057 560.077708 0.286031391 
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Supplementary figure 2 – U87shBCAT1 conditioned medium stimulates T cell proliferation.  
T cells were enriched out of the total PBMCs isolated from a healthy donor using a negative selection protocol 
(Miltenyi Biotec). Isolated T cells were cultured with conditioned medium from U87-MG cells expressing normal 
BCAT1 levels (nt) or decreased BCAT1 levels (shBCAT1) and stimulated with IL-2 and PHA for 6 days. Proliferation 
was determined by CFSE dilution. Values are mean of two technical replicates. Data generated jointly with Soumya 
Mohapatra and Dr. Christiane Opitz, Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 
Heidelberg, Germany. 
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